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ABSTRACT
Angelman syndrome (AS) is a rare genetic disorder affecting 1/10,000 to 1/20,000 births. This
disorder arises through the genetic disruption of the maternal UBE3A allele, which when coupled
with epigenetic silencing of the paternal allele UBE3A allele, gives rise to an absence of UBE3A
protein in the central nervous system. Clinical manifestations of the syndrome vary in severity and
include poor motor function, deficits in language and severe intellectual impairments. Previous
research in the Angelman syndrome mouse model revealed abnormalities in dendritic spine density
and morphology of hippocampal pyramidal cells. As seen in humans with AS, mice show
abnormal behavioral characteristics that include deficits in motor coordination and ability as well
as hippocampal dependent associative fear conditioning. Physiologically, these animals exhibit
severe deficits in long-term potentiation (LTP) when compared to wildtype littermates.
In an attempt to reduce the time from laboratory study to human translation, we began to
search a small molecule library for established compounds with the ability to improve the
behavioral and physiological defects normally associated with the AS mouse. One compound,
minocycline, was found to normalize the density of dendritic spines in the hippocampus as well as
recover the associative memory of AS mice. Moreover, a significant increase in LTP after thetaburst stimulation was also observed in area CA1 hippocampal pyramidal neurons of AS mice
treated with minocycline when compared to saline vehicle control mice. These results suggest
treatment with minocycline improves synaptic function and learning and memory of AS mice and
may provide similar improvements to patients with Angelman syndrome.
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Twenty-five participants ages 4-12 were enrolled in a clinical trial examining the safety and
tolerability of minocycline in children with Angelman syndrome. Patients were evaluated at 3 time
points, baseline (T1), after 8 weeks of treatment (T2) and again 8 weeks after the drug was
discontinued (T3). Each evaluation was identical and included laboratory testing, EEG recording
and neuropsychological examination. Results of the study showed minocycline was safe and well
tolerated with only minor adverse effects reported. While no change was observed in EEG
recordings, significant increases in the mean clinical global impressions severity scale score were
observed after treatment with minocycline. Moreover, participants showed significant
improvement in the raw scores of the communication and self-care domains of the Bayley Scale
of Infant and Toddler Development, 3rd Edition. These results show for the first time, a therapeutic
with the ability to improve the characteristic behaviors of Angelman syndrome.
Unfortunately, currently available neuropsychological measures were found to be
insensitive to the behavioral phenotype of AS. The primary outcome measure, the Bayley Scale of
Infant and Toddler Development, 3rd Edition relies on verbal communication and for the examinee
to perform specific tasks on command. These testing methods are not compatible with this patient
population and resulted in raw scores outside of 2 standard deviations from the mean. The inability
of the participants to perform on these exams led us to develop a novel outcome measure; one that
relies on observation rather than verbal communication. 9 children with AS and 7 healthy children
were enrolled in an observational study in which 30 minutes of free play activity was video
recorded. Using behavioral coding software, 3 independent raters quantified stereotypical AS
behaviors as well as communication methods. Speech attempts were categorized into five
difference types of vocalizations and revealed children with AS used less advance forms of
vocalization consisting mostly of phonation control. Phonetic inventories show mostly front or
vii

back vowel usage suggesting little tongue movement occurs during speech production. These
results suggest deficits in verbal ability may be related to a childhood apraxia of speech.
Impairments in balance and motor coordination have been associated with AS. In an
attempt to measure gross motor function, spatiotemporal gait parameters were collected using an
electronic walkway and gait analysis software. Results show the gait of children with AS most
resembles that of patients with ataxia but without cognitive impairment. In an attempt to develop
a single quantitative measure able to describe the severity of gait-related disability, statistical
methods were used to create a gait index for patients with AS. The results of this study provides
AS researchers with the tools necessary to accurately measure changes in behavior and gait during
the clinical evaluation of potential therapeutics.

viii

CHAPTER 1

INTRODUCTION
Angelman Syndrome
In 1965, Dr. Harry Angelman first described three children, of normal birth to healthy
parents, which exhibited similar symptoms including microcephaly, frequent fits, profound mental
retardation, lack of speech, ataxia, easily provoked laughter and a protruding tongue (Angelman
1965). Initially coined as “happy puppet children”, this derogatory description was later renamed
to Angelman syndrome (AS). Further research revealed other common features of the syndrome
that include, but are not limited to feeding/suckling problems, delays in motor abilities,
hyperreflexia, strabismus, widely spaced teeth and seizure with electroencephalogram (EEG)
abnormalities (Clayton-Smith and Pembrey 1992).
Clinical Presentation
Diagnostic Criteria
Published in 1995, a revised consensus statement was published that summarized the
clinical features of Angelman syndrome in an attempt to facilitate the diagnosis of patients in
which Angelman syndrome is suspected (Williams, Beaudet et al. 2006). The developmental
histories of Angelman patients reveal normal prenatal and birth history and an absence of major
defects. As neonates and infants, these patients have difficulty feeding and, by 6-12 months of age,
truncal hypotonicity with jerky movements of the limbs become evident. Patients will exhibit a
progressive but delayed development. Laboratory values will reveal normal metabolic,
1

hematologic and chemical profiles. Normal brain structure, with or without cortical atrophy or
dysmyelination, will be observed using MRI or CT scans (Williams, Beaudet et al. 2006).
Infants with AS will exhibit truncal hypotonia and present as floppy with hypertonicity of
the limbs. Consistent (100%) clinical features of AS include a severe developmental delay and
disorders in balance and movement. While typically developing children begin to sit independently
between the ages of 4 to 7 months, children with AS begin to sit unsupported at approximately 12
months of age. Moreover, children with AS do not progress to crawling (or cruising) until 18 to
24 months of age while a typically developing child will begin to pull up and ambulate
independently at 9 months. Walking will be delayed until an average age of 4 years old and will
be ataxic and dyspraxic with a wider than normal base of support and tremulous movement of the
arms and legs. Frequent laughter, smiling and happy demeanor are behaviorally unique to patients
with this syndrome. This behavior is accentuated by hypermotoric behaviors such as hand flapping
or waving motions (Clayton-Smith and Pembrey 1992). While there are several other features of
AS (Table 1-1) that occur less frequently (>80%), the most severe is seizure, which emerges prior
to 3 years of age and confirmed by abnormal electroencephalogram (EEG) (Williams, Beaudet et
al. 2006)
Polygraphic Pattern Profile of Angelman Syndrome
Several reports have shown children exhibiting the clinical features of AS also exhibit
characteristic electroencephalogram (EEG) wave patterns even if the patients have had no history
of seizure (Boyd, Harden et al. 1988). Clinical research agrees in the existence of 3 main
characteristic EEG patterns including: 1) Prolonged runs of high amplitude (200-500µV) rhythmic
2-3Hz (delta) activity over the frontal regions with superimposed interictal epileptiform discharges
(83.5% prevalence). 2) High amplitude rhythmic 4-6Hz (theta) activity, prominent in the occipital
2

region with spikes facilitated by eye closure. 3) High amplitude (<200µV) spikes and sharp waves
mixed with 3-4Hz components mainly in the posterior facilitated by eye closure (Laan and Vein
2005, Vendrame, Loddenkemper et al. 2012). The aforementioned wave patterns are so consistent,
even amongst the various genotypes, Vedrame et al. suggest these patterns should be used as a
biomarker in the diagnosis of the syndrome (Vendrame, Loddenkemper et al. 2012). For example,
in a separate study researchers evaluated 144 patients with severe epilepsy and cognitive
impairment. Of those patients, 10 met diagnostic criteria of Williams et al. and one, despite the
absence of clinical features of AS, was identified and diagnosed (confirmed by molecular testing)
with AS. The results of this study suggest EEG findings are indicative of AS and, even in the
absence of clinical findings, genetic testing should be completed when specific EEG patterns
characteristic of AS are observed (Buoni, Grosso et al. 1999).

Table 1-1. 2005: Clinical Features of Angelman Syndrome
Frequently occurring (more than 80%)
Disproportionate growth in head circumference, resulting in microcephaly
Seizures
Abnormal EEG with characteristic pattern
Associated (20%-80%)
Flat occiput
Occipital groove
Protruding tongue
Tongue thrusting
Sucking/Swallowing disorders
Feeding problems
Hypopigmented skin, light hair and eye color
Increased sensitivity to heat
Uplifted and flexed arm position during ambulation
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Prognathia
Wide mouth
Widely spaced teeth
Frequent drooling
Excessive chewing/mouthing
behaviors
Strabismus
Hyperreflexia
Wide based gait

Differential Diagnosis
Several conditions and phenotypes (Table 1-2) mimic the clinical features of Angelman
syndrome resulting in the potential for misdiagnosis (Clayton-Smith and Pembrey 1992, Williams,
Lossie et al. 2001). While a significant overlap in the clinical features exists between the conditions
Table 1-2. Conditions with Clinical Features Overlapping Angelman Syndrome
Chromosome Disorders
Single Gene Disorders
Symptom complexes
 Cerebral Palsy
 22q13.3 terminal
 Rett syndrome
 Lennox-Gastaut
deletions
syndrome
 X-Linked thalassemia
 Del 15q12 (Pradersyndrome (ATR-X)
 Static encephalopathy
Willi)
 Methylene
 Childhood Autism
 Dup 15q12
tetrahydromfolate
 Mitochondrial
reductase deficiency
 Del 2q22-q23
encephalopathy
 Gurrieri syndrome
 Others
 Pervasic developmental
disorder

listed above, few reports of incorrect diagnoses exist. Of those reported, Angelman syndrome was
mistaken for X-linked alpha-thalassemia (ATRX), ataxic cerebral palsy, and Rett syndrome, or
vice versa (Clayton-Smith and Pembrey 1992, Williams, Lossie et al. 2001).
Similar to Angelman syndrome, ATR-X is characterized by distinctive craniofacial
features, such as small head circumference and widely spaced eyes. These patients also display
hypotonia, severe developmental delays and intellectual disability which, often times, results in
inability to walk independently or develop speech. In contrast to Angelman syndrome, patients
with ATRX often exhibit anomalies of genitals, tented vermilion of the upper lip and thick or
everted vermilion of the lower lip (Stevenson 1993). Aside from cytogenetic analysis, in families
with an X-linked pattern of inheritance the diagnosis of Angelman syndrome can be excluded.
Moreover, positive mutation testing for X-linked nuclear protein can help to delineate ATR-X
from Angelman syndrome.
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Misdiagnosis has been shown to occur when patients with cerebral palsy (CP) exhibit ASlike traits, including hypotonia, difficulty feeding and a happy demeanor. Some patients with CP
exhibit an ataxic or unstable gain and tremulous movements. Magnetic Resonance Imaging of the
brain of a patient with CP may be helpful by revealing mild atrophy. While positive results of the
molecular studies described above offer a definitive diagnosis, it remains difficult to delineate
between AS and CP when a patient exhibits only clinical symptoms (idiopathic AS).
Of all the mimics mentioned in Table 1-2, Rett syndrome (RS) is the most common in
female infants and toddlers. Schieffer et al. reported two cases in which female children with
microcephaly, prominent lower jaw and protruding tongue were initially diagnosed with
Angelman syndrome. Like AS, these patients exhibit muscular hypotonia, seizure,
ataxic/dyspraxic gait, microcephaly and seizure disorder. In most cases RS is easily distinguished
from AS given the higher cognitive ability of children with AS than those with Rett (Williams,
Lossie et al. 2001). For example, in the case of Schieffer et al., having initially diagnosed 2 female
children with AS, a revised diagnosis of Rett syndrome occurred after the patients showed
regression in motor and verbal ability (Scheffer, Brett et al. 1990, Clayton-Smith and Pembrey
1992). Since the publication of their report, mutations in the gene coding for DNA methyl binding
protein (MECP2) has now been identified as the underlying cause of Rett syndrome and the use
of molecular testing has made it easier to offer a definitive diagnosis. While it seems that RS only
affects females, it is possible for male children to present with the disorder. However, considering
the MECP2 gene locus is found on the X chromosome, unlike females, in males only one gene
copy exists. Without a second normal copy of MECP2, males experience severe disability from
the time of birth and die shortly thereafter. Still, more recent research has revealed mutations in
other genes (i.e. CDKL5 and FOXG1) that may contribute to or be the cause of RS in a lower
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number of patients. Taken together, physicians should be cautious diagnosing AS when they are
presented with female children exhibiting the clinical features of AS but with regression of
physical abilities.
Molecular Basis of Angelman Syndrome
Angelman syndrome results from a deficiency in the maternally derived homolog of the
human chromosome 15q11-q13, the coding region that includes an E3 ubiquitin ligase, UBE3A
(E6-AP) (Matsuura, Sutcliffe et al. 1997). By 1999, research had shown the disorder to be the first
single gene disorder of the ubiquitination pathway and demonstrated a pattern of imprinting that
was specific to the brain. Moreover, for the first time, scientific evidence was presented revealing
the imprinting center of this region controlled genes that were necessary for long-term potentiation
(LTP) (Jiang, Lev-Lehman et al. 1999). Encoded in the Ube3a gene are two RNA transcripts, the
sense (maternally derived) and anti-sense (paternally derived). In 2003, Yamasaki et al. reported
the sense strand of RNA was preferentially expressed in neurons but biallelic expression was
observed in other glial cells (Yamasaki, Joh et al. 2003). Further research revealed UBE3A protein
expression was tissue specific, with minimal protein concentration levels found in all neuron types
of the hippocampus, hypothalamus, olfactory bulb, cerebral cortex, striatum, thalamus, midbrain
and cerebellum in AS mice while a greater than 50% expression level of UBE3A was found in
heart and liver tissues (Richard, Terry et al. 2010).
Due to the preferential expression of the sense strand, any alteration (Table 1-3), the most
common being a large (4 Mb) deletion, in the maternal gene results an absent or mutated version
of the protein product leading to Angelman syndrome (Jiang, Lev-Lehman et al. 1999).
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Table 1-3. Molecular Mechanisms of Angelman Syndrome
Type

Mechanism

Ia
Ib
IIa
IIb
IIIa
IIIb
IV
V

4-Mb interstitial maternal del15q11-q13
Unbalanced translocation or inherited interstitial deletion
UPD maternal deficiency with normal parental chromosomes
UPD with predisposing parental translocation
Imprinting mutation with deletion of IC
Imprinting mutation without detectable deletion of IC
Point mutations in UBE3A
AS phenotype with no identifiable molecular abnormality

% Of the AS
population
65 – 75 %
< 1%
3-5%
<1%
3%–5%
3%–5%
4%–6%
10%–14%

Diagnostic Molecular Testing
Until the early 1990’s, Angelman syndrome was diagnosed clinically. That is, an individual
was said to have AS if they met the diagnostic criteria mentioned above. However, more recently
tests examining the genes of an individual have come online and allow physicians to offer a
diagnosis of AS with near certainty. A common test used in the diagnosis of genetic abnormalities
such as AS is a cytogenetic analysis. In this test, a karyotype of the patient’s chromosomes is
made by pairing the chromosomes and ordering them from largest to smallest. In doing this, the
geneticist can determine if the proper number of chromosomes are present and, in some cases,
large deletions can be observed on a particular chromosome. Unfortunately, this test has poor
resolution for small deletions of a particular allele which is common in Angelman syndrome.
Methylation Testing
Methylation patterns, specific to the parent of origin (maternal vs. paternal) can be detected
using several different techniques. In general, lymphocytes from an individual’s whole blood
sample are harvested and their DNA is isolated. Using techniques such as the methylation specific
PCR test, the presence of methylation patterns contributed by both or either of the parents can be
determined. Under normal circumstances a sample contains patterns specific to both the mother
and the father when the UBE3A allele is examined. However, when the maternal methylation
7

pattern is missing, the patient is diagnosed with Angelman syndrome. While a definitive diagnosis
of AS can be made using methylation testing techniques, further testing is still required to
determine the particular molecular abnormality, such as, deletion size, uniparental disomy (UPD)
or imprinting center defect (ICD) that exists.
Fluorescent in situ Hybridization (FISH)
The FISH test is used to determine presence or absence of a specific portion of DNA code.
Complementary sequences to the UBE3A allele (a probe) are created using nick translation to add
a nucleotide tag (-DigdUTP or Biotin-dUTP) and these probes allowed to hybridize with the DNA
from cells fixed to a slide. The sample is then incubated with antibodies (anti-Dig or Avidin) and
a fluorophore tag. Using fluorescent microscopy, the sample is examined for the presence of 2
fluorophore tags which indicate two copies of UBE3A exist. However, if only one fluorescent tag
is observed, the test has confirmed a deletion of one of the UBE3A alleles. To determine if AS was
caused by a deletion, the results of this test are combined with the results of a methylation study.
For example, if the methylation study is positive for the absence of the maternal methylation
pattern and the results of the FISH are positive for the absence of one copy of UBE3A, the patient
is said to have Angelman syndrome due to a deletion of the maternal allele. Similarly, if the FISH
test is positive, but the paternal methylation pattern is missing, the patient is diagnosed with PraderWilli syndrome. Finally, when the methylation test is positive for Angelman syndrome but the
FISH test is negative, further testing will be needed to determine if genetic abnormality is an UPD
or ICD.
Microsatellite Analysis
While methylation testing can be used to identify patients with UPD, large deletions and
imprinting mutations, this testing cannot be used to determine which of the aforementioned genetic
8

abnormalities are present in a patient with a positive methylation test. Therefore, further testing is
warranted when patients present with the clinical features of AS, have a positive methylation result
but are shown to exhibit negative FISH results. To determine if the underlying cause of AS is UPD,
a blood sample is taken from both the patient and the parents to identify the inheritance of
molecular polymorphisms. PCR primers unique to the UBE3A locus are used to amplify regions
(PCR) of DNA which include microsatellites, which are simple sequence repeats commonly used
as a genetic marker. These microsatellites are unique to the parent of origin and, when all the
samples (patient, father and mother) are compared, inheritance can be determined. In the case of
AS caused by UPD, only the paternal sequence will be observed in the patient’s sample. If the
sample includes both maternal and paternal inheritance, ICD is inferred.
UBE3A Sequencing
In approximately 15% of patients exhibiting the clinical features of AS, the testing
mentioned above will not provide a definitive diagnosis and even more testing is required. With
the recent advancements in gene sequencing, several different techniques can be used to determine
the exact order of nucleotides of an individual’s DNA. Using these techniques, the specific
sequence of the UBE3A gene can be determined and mutations in the genetic code identified.
Several anomalous conditions can occur and include: 1) The introduction of polymorphisms that
have no impact on the protein product. 2) Mutation of the genetic code that alters the structure of
the protein product resulting in aberrant function. 3) The introduction of an early stop codon
resulting in a truncated, non-functional protein product. 4) An addition or deletion of bases
resulting in a mutated, non-functional protein product.
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Idiopathic Angelman Syndrome
There is an estimated 10-14% of patients in which a molecular abnormality cannot be
detected. However, these patients exhibit the same characteristic physical, behavioral and
cognitive features of Angelman syndrome. These patients are diagnosed based on the clinical
symptoms and with support provided by signature EEG patterns observed in 100% of patients
(discussed above).
Standard of Care in Treatment
While people with Angelman syndrome have the potential for a normal life span, most
individuals will have severe developmental delays, limited or non-existent speech and both fine
and gross motor disability. There is no specific treatment of the syndrome but patients may benefit
from physical, occupational and behavioral therapies. Special education techniques can be
employed to maximize learning in this patient population. Treatment patients with AS receive most
commonly consists of feeding supplementation, especially early in life, and the management of
the medical and developmental issues, such as seizure and mobility. While several medications
exist for the treatment of seizures, there is no medication currently available to treat the underlying
cause of AS; the lack of a functional UBE3A protein.
Neuropsychological Assessments
Few reports exist detailing the cognitive and behavioral performance of patients with
Angelman syndrome on neuropsychological measures. As part of another research study testing
the effect of two medications: betaine and folic acid, 20 children ranging in age from 5 months to
10 years of age were tested. The neuropsychological measures employed were the Bayley Scale
of Infant and Toddler Development, 2nd Edition (BSID-II) and the Vineland Adaptive Behavior
Scales – Interview Edition (VABS). The results of this study revealed cognitive scores that fell
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within the severe to profound range of cognitive impairment equating to the developmental age of
3-17 months regardless of chronologic age. Moreover, severely delayed motor skills as well as
delays in adaptive behaviors were also noted. It is important to point out, these children were
unable to achieve standardized scores, therefore only raw scores (Table 1-4) could be used to
describe their ability (Peters, Goddard-Finegold et al. 2004). Similarly, our laboratory recently
completed a clinical study in which 25 children were evaluated using the BSID, 3rd Edition (BSIDIII) as well as the VABS (Table 3-2) and found severe deficits in cognition, motor ability and
adaptive behaviors (Grieco, Ciarlone et al. 2014). The inability of this population to perform on
these, and all other, standardized measures results in a “floor effect” and precludes our ability to
accurately compare the severity of symptoms between individuals with AS and masks any changes
that may be observed when a therapeutic is applied resulting in the potential to report false negative
Table 1-4. Developmental Age Scores and Raw Score Breakdown According to Chronological
Age
Chronological Age (Months)
Developmental Age (Months)
Raw Score
5
3
34
15
6
61
16
5
53
23
7
68
25
6
65
26
7
70
26
6
65
26
7
68
35
6
63
40
7
67
47
15
101
49
9
76
51
7
67
51
9
76
56
5
54
67
14
94
69
7
67
95
17
108
123
16
103
The results shown by Peters et al. (2004) equate to profound cognitive deficits and raw scores below the
minimum score required to calculate a standard score (a “floor effect”). However, these results do not
reflect the ability of the patient or the severity of the patient’s symptoms. They only reveal the number
of tasks the patient was willing to perform when asked.
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results.
The Biochemistry of UBE3A
UBE3A is a member of a class of proteins known as E3 ligases that are responsible for
attaching an ubiquitin molecule to a specific protein target marking it for proteasomal degradation.
The carboxy-terminal end of the UBE3A protein contains a 350 amino acid hect (homologous to
E6-AP carboxy-terminous) domain. A segment of 100 amino acids at the end of the hect domain
contain the catalytic site, which is responsible for transfer of ubiquitin molecules from the E3
ligase to the substrate target. The substrate binding site is an 18 amino acid segment located in the
central section of the UBE3A protein (Nawaz, Lonard et al. 1999). In the ubiquitination process,
4 different proteins work in concert attaching molecules of ubiquitin to a protein targeted for
proteasomal degradation (Figure 1-1).

Figure 1-1. Ubiquitination Consist of 4 Steps: 1) Activation of ubiquitin (Ub). 2) Transfer
of ubiquitin to the E2 ubiquitin-conjugating enzyme. 3) A specific E3 ubiquitin ligase
recognizes its target and catalyzes the transfer of the Ub molecule to the target substrate. 4)
Ubiquitinated substrate is degraded via the proteasomal pathway.
Initially, the UBE3A (E6-AP) protein was identified by its role in the ubiquitination of the
E6 protein of the human papillomavirus promoting the degradation of p53 (Huibregtse, Scheffner
et al. 1991, Huibregtse, Scheffner et al. 1991). However, further research has shown other targets
exist including the HHR23A, which is involved in nucleotide excision repair and MCM7, part of
the pre-replication protein complex (Kuhne and Banks 1998, Kumar, Talis et al. 1999) . Finally,
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Nuber et al. has shown E6-AP (UBE3A) is a target of itself and when ubiquitinated, the ligase is
inactivated and then directed to the proteasome for degradation (Nuber, Schwarz et al. 1998).
In addition to its role during proteasomal degradation, UBE3A also acts as a transcriptional
activator of the human progesterone receptor and other members of this receptor superfamily.
However, when Nawaz et al. examined mutant forms of human E6-AP, they showed
transcriptional activation remained intact while proteasomal dysfunction was observed (Nawaz,
Lonard et al. 1999). This research showed mutation in the hect domain, which causes catalytic
dysfunction of the UBE3A, did not affect transcriptional activation. Their research suggests that
Angelman syndrome is the result of a defect in the proteasomal degradation pathway.
To determine where UBE3A resides within the brain, UBE3Ayfp reporter mice with a knockin mutation which fused a yellow fluorescent protein (YFP) to the C-terminus of UBE3A were
created. Results of the study showed maternal UBE3Ayfp was expressed in high levels in the
pyramidal cells of the CA3 region of the hippocampus as well as most other brain regions including
the cortex, thalamus, olfactory bulb and cerebellum. In cell culture, UBE3A was detected in both
the pre and postsynaptic densities (Dindot, Antalffy et al. 2008). Finally, quantification of both
dendritic spine densities reveals significantly fewer spines on the hippocampal pyramidal cells of
mutant mice when compared to wild type (Scott, Barbara et al. 2007). These results suggest the
lack of a functional UBE3A protein results in structural abnormality of the dendritic spines and
provides an explanation for the observed deficits in spatial memory in both mice and humans.
The AS Mouse Model
In 1998, the Angelman syndrome mouse model was created by replacing a 3kb genomic
DNA fragment in exon 2. This mutation results in the deletion of one hundred of the most Nterminal amino acids causing a shift in the reading frame and an inactive isoform of the UBE3A
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protein. Neither wild-type (WT, m+/p+) nor paternally deficient (m+/p-) mice exhibit any
phenotypic abnormalities on postnatal day 8. However, in mice with a maternal deficiency (AS,
m-/p+) Jiang et al. observed a significant reduction in the total body weight, brain, cerebral cortex
and cerebellum (Jiang, Armstrong et al. 1998). When these mice were tested on the accelerating
rotating rod, the AS animals exhibited shorter latency to fall times than their WT littermates, the
latter showed improvement over time as a result of motor learning. Associative fear conditioning
is a test of learning in which mice associate a particular environment (context) with an aversive
stimulus (foot shock). This form of learning has been shown to be hippocampal dependent and can
be assessed by measuring the amount of time a trained animal freezes, a behavior characterized by
a motionless, hunched posture. When AS mice were compared to WT animals, a 20% reduction
in freezing was observed, suggesting mutant mice exhibit deficits in associative learning and
memory. These results are supported by a decrease in field excitatory postsynaptic potentials
(fEPSP’s) measured from the Schaffer collateral synapses in area CA1 while there was no
difference between genotypes when input/output, fiber volley amplitude and paired pulse
facilitation measures were analyzed. This suggests deficits in long-term potentiation are isolated
to the post synaptic density. Taken together, this mouse model recapitulates the phenotypes
observed in humans with Angelman syndrome.
Clinical Research to Date
The AS Natural History study is an ongoing longitudinal study of children and adults with
AS examining the possible genotype-phenotype correlation(s) between the molecular subclasses
of the disease (Gentile, Tan et al. 2010). The study is ongoing at the Children’s Hospital Boston
as well as 5 other sites. Outcome data collected in this study includes annual medical histories,
physical examinations, and neurodevelopmental assessments using the Bayley Scales of Infant and
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Toddler Development (BSID-III), Vineland Adaptive Behavior Scales, Preschool Language Scale
and the Aberrant Behavior Checklist. An electroencephalogram (EEG) is performed on each
participant every other year as well. Currently the study has 200 participants enrolled representing
children ages 2 to 5 years old.
The AS Therapeutic Trial is an open label trial in AS children under the age of 5 years old
to determine whether a one year treatment with the combination of Metafolin, vitamin B12,
creatine and betaine can improve the neurodevelopment by promoting methylation and therefore
expression of the normally silent paternal UBE3A. The neurodevelopmental assessments used in
this study were the same as listed above in the AS Natural History Study. This clinical trial was
completed and preliminary data suggests that the treatment regimen was not beneficial.
Recently a multicenter, phase I trial examining the safety of Levodopa and Carbidopa was
completed in a study cohort of 4 to 12 year old patients with AS. The same group of researchers
are now planning a large phase II/III trial of the same medication. At the time this dissertation was
written, the results of this study had not been published.
More than 10 years ago, researchers observed positive effects after the administration of
minocycline (MC) in mouse models of Huntington’s disease. The reversal of symptoms after the
administration of MC in two separate studies led researchers to believe the drug could be used as
a possible therapeutic agent (Chen, Ona et al. 2000, Yamamoto, Lucas et al. 2000). Since then
several translational studies have been conducted and shown MC is well tolerated, safe and has
the ability to improve the symptoms of several neurologic diseases including Parkinson’s disease,
Huntington’s disease, multiple sclerosis and amyotrophic lateral sclerosis (Denovan-Wright,
Devarajan et al. 2002, Blum, Chtarto et al. 2004, Thomas, Ashizawa et al. 2004, Kim and Suh
2009). Studies testing the long-term use of MC to treat other diseases such as rheumatoid arthritis
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and acne also show the drug is tolerated during long-term use, possesses neuroprotective
characteristics and results in only minor adverse effects (Goulden, Glass et al. 1996, O'Dell,
Blakely et al. 2001, Van Den Bosch, Tilkin et al. 2002, Bonelli, Heuberger et al. 2003, Utari,
Chonchaiya et al. 2010).
More recently, a retrospective study examining the documented side effects of MC in 50
fragile X patients was completed. Participants of this study represented a mean duration of
treatment of 3.5 months with a dosage ranging from 25mg to 200mg per day. The study results
indicated, on average, a change in the participant’s behavior was observed after 3.5 weeks of
treatment with MC. In most cases where a side effect was reported, it was mild gastrointestinal
distress including loss of appetite and diarrhea that lasted for the first few days of treatment.
Discoloration of the teeth is a side effect most feared in younger patients; however, there was no
report of this side effect in this study population. This study showed there was no significant
association between age and adverse effects. An improvement in language ability, attention, social
communication and anxiety measured by the parent’s impression was reported. This study proves
the use of MC to treat fragile X (and other neurologic disorders) in younger patients is reasonably
safe and may result in behavioral improvements after a short treatment period (Utari, Chonchaiya
et al. 2010).
Tetracycline medications have been observed not only to have antimicrobial effects but
also anti-inflammatory properties. This characteristic has been attributed to their ability to inhibit
pro-inflammatory proteins

such

as

matrix

metalloproteinase

(MMP’s).

Since

most

neurodegenerative diseases have an inflammatory component, it stands to reason that MC could
lessen the damaging effects of the inflammatory process by altering the biochemical pathways
leading to neuronal damage.
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Matrix metalloproteinases also play a role in the plasticity and morphology of dendritic
spines (DS). Dendritic spines (DS) are small membranous protrusions extending from the dendrite
of a neuron. A component of the synaptic junction, the DS receives excitatory signals from the
synapse of an adjacent neuron. Proper number and morphology of DS’s is required for signal
propagation resulting in normal brain function and cognition. A change in the number or
morphology of DS’s has been implicated in the pathogenesis of several neurologic disorders
(Kasai, Fukuda et al. 2010, Pan, Aldridge et al. 2010, Penzes, Cahill et al. 2011). Histologic
examination of AS mice and human postmortem hippocampi revealed a decrease in the number of
dendritic spines resulting in severe developmental deficits. However, after treatment with MC an
increase in spine density was noted on excitatory neuronal dendrites leading to an improvement in
cognition and behavior (Bilousova, Dansie et al. 2009, Grossman, Aldridge et al. 2010). Literature
suggests MMP-7 is a key regulator of the extracellular matrix and which plays a vital role in the
development of healthy, normally functioning DS’s (Bilousova, Rusakov et al. 2006, Ethell and
Ethell 2007). Given MC interacts with MMP’s, a potential mechanism associated with MC is
influencing morphology of DS’s and subsequent modification of synaptic function or overall
connectivity.
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CHAPTER 2

MINOCYCLINE INCREASES LONG-TERM POTENTIATION AND ASSOCIATIVE
LEARNING IN THE ANGELMAN SYNDROME MOUSE MODEL
Background
Angelman syndrome is a rare genetic disorder occurring in 1/10,000 to 1/20,000 births
(Clayton-Smith and Pembrey 1992, Petersen, Brondum-Nielsen et al. 1995, Steffenburg, Gillberg
et al. 1996, Buckley, Dinno et al. 1998, Williams 2013). The disorder arises through the genetic
or biochemical disruption of the maternal UBE3A allele, which when coupled with epigenetic
silencing of the paternal UBE3A allele, gives rise to an absence of UBE3A protein in the central
nervous system. Clinical manifestations of the syndrome vary in severity and include poor motor
function, deficits in language and severe intellectual impairments. Patients with Angelman
syndrome also exhibit characteristic behaviors including: fascination with water, hyperexcitability (hyperactivity and hand flapping), inability to sense danger, tremor, lack of attention,
reduced eye contact, attention-seeking behavior, and excessive laughter and smiling.
Approximately 80% of children diagnosed with AS also suffer from seizure of various types and
severity (Clayton-Smith and Laan 2003, Williams 2005, Pelc, Cheron et al. 2008). The diagnosis
of Angelman syndrome is based on clinical evaluation and often confirmed using genetic testing.
Several genetic mechanisms involving the maternal UBE3A gene result in the expression of the
Angelman phenotype including a deletion, mutation, defect in the imprinting center or a
uniparental disomy of the gene region containing UBE3A. Still, a small number of patients (15%)
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exhibit the symptoms and behavioral characteristics of Angelman syndrome but no molecular
mechanism can be detected. In addition to the clinical manifestations, many children with AS
exhibit distinct EEG patterns that are specific to Angelman syndrome and are often used in the
diagnosis of the syndrome when a molecular diagnosis cannot be confirmed (Laan and Vein 2005,
Vendrame, Loddenkemper et al. 2012).
Normal expression of the UBE3A gene (chromosome 15q11q12) results in the production
of ubiquitin protein ligase E3 (UBE3A), an enzyme that is found in axons, dendrites and the soma
of hippocampal neurons and is required for proteasomal degradation of intracellular proteins as
well as for normal synaptic development (Dindot, Antalffy et al. 2008). Biallellic expression of
UBE3A is seen in peripheral tissues; however, in neurons the maternal UBE3A allele is
preferentially expressed while the paternal allele is imprinted and is silenced. Therefore any
disruption of the maternal allele results in a dysfunctional or absent UBE3A protein resulting in
Angelman syndrome (Chan, Clayton-Smith et al. 1993, Kishino, Lalande et al. 1997, Sartori, Anesi
et al. 2008).
The number and morphology of dendritic spines change throughout normal mammalian
life. These dynamic characteristics contribute to the ability to form long-term memories. Abnormal
spine shape and number has been implicated in several neurologic and neuropsychiatric disorders
such as autism spectrum disorder, Fragile X syndrome, schizophrenia and Alzheimer’s disease
(Kasai, Fukuda et al. 2010, Pan, Aldridge et al. 2010, Penzes, Cahill et al. 2011). Examination of
pyramidal neurons of the hippocampus and cortex as well as cerebellar Purkinje cells from mice
with Angelman syndrome revealed normal dendritic branching but altered dendritic spine
development (Figure 2-1) including abnormal spine morphology, number and length (Dindot,
Antalffy et al. 2008). Moreover, the autopsy of a 21-year old female with Angelman syndrome
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revealed atrophy of cerebellar Purkinje cells. Golgi impregnation of pyramidal neurons in the
human visual cortex showed a dramatic decrease in the dendritic arborization, abnormal
morphology and decreased number of dendritic spines (Jay, Becker et al. 1991). The pathology
described by these reports provides potential evidence for the cognitive impairment observed in
Angelman syndrome.

Figure 2-1. Abnormal Dendritic Spine Morphology of Cerebellum, Hippocampus and
Cortex of Mice with Maternal Deficiency for UBE3A.

A) Dindot et al. (2008) show AS mice exhibit abnormal dendritic spine morphology in
cerebellum, hippocampus and cortex of AS mice. B & C) Quantification of dendritic spine
number revealed a significant decrease in the spine density of area CA1 and layer 3-5
pyramidal neurons. The length of dendritic spines of CA1 pyramidal neurons was also
decreased in the AS mouse. D) Spine length was decreased in are CA1 pyramidal neurons as
well.
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Minocycline, a second-generation tetracycline antibiotic medication, is a small (495kDa),
lipophilic molecule that readily crosses the blood brain barrier (O Ulgen, G Field et al. 2011).
These characteristics allow minocycline to penetrate the central nervous system more readily than
other members of the tetracycline family. The drug has a number of biologic effects other than
anti-microbial activity including: 1) anti-inflammatory properties 2) anti-apoptotic properties 3)
inhibition of proteolysis and 4) angiogenic properties (Garrido-Mesa, Zarzuelo et al. 2013). The
administration of minocycline reduces the severity and progression of disease and in some cases
prolongs the lifespan of animal models (Yong, Wells et al. 2004, Garrido‐Mesa, Zarzuelo et al.
2013). For example, when minocycline was administered to the Fragile X mouse model, Bilousova
et al. showed changes in the morphology of dendritic spines (Figure 2-2) of cultured hippocampal
neurons from elongated (immature) to mushroom shaped (mature) accompanied by an

Figure 2-2. Minocycline Increased the Number of Mushroom
Shaped Dendritic Spines in Cultured Primary Neurons from
Fragile X Mice.
Cultured primary neurons of Fragile X mice treated with
minocycline showed increased number of mushroom shaped
(mature) dendritic spines compared to untreated neurons (left).
improvement in spatial memory in a Fragile X mouse model (Bilousova, Dansie et al.
2009). Studies of the effect of minocycline on humans with Fragile X syndrome revealed
significant behavioral improvement in the subscale scores of the Aberrant Behavior ChecklistCommunity, as well as the Visual Analog Scale and Clinical Global Impressions Scale scores
(Paribello, Tao et al. 2010). Minocycline also decreases neuroinflammatory effects by down21

regulating proinflammatory cytokines and microglial activation (Yrjanheikki, Keinanen et al.
1998).
Although the mechanism(s) of action is unclear, recent studies suggest minocycline may
play an important role in modulating synaptic function. For instance, some have suggested
minocycline may affect the activity of matrix metalloproteinase 9 whose targets include structural
proteins of the extracellular matrix (ECM) as well as cell surface molecules and pericellular nonmatrix proteins. The catalytic property of these zinc-dependent (Zn2+) proteinases is therefore
effective at regulating cell behavior in the context of synaptic plasticity (Sternlicht and Werb
2001). Matrix metalloproteinases have also been shown to play a role in the plasticity and
morphology of dendritic spines as well as aid in the development of healthy, normally functioning
dendritic spines (Bilousova, Rusakov et al. 2006, Ethell and Ethell 2007). Minocycline’s positive
neurologic effects and its interaction with MMP’s provides a possible mechanism for the observed
changes in the morphology of dendritic spines and subsequent modification of synaptic function
or overall connectivity (Blum, Chtarto et al. 2004).
Considering minocycline’s low risk of adverse effects, low chance of forming antibiotic
resistance, potential to normalize synaptic structure and its ability to improve behavioral
performance in humans led us to posit that administering minocycline to mice with Angelman
syndrome may ameliorate the CNS symptoms associated with AS, improve behavioral
performance and restore synaptic function.
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Materials and Methods
Ethics Statement
Animal testing procedures were approved by the Institutional Animal Care and Use
Committee at the University of South Florida and complied with the National Institutes of Health
guidelines for the care and use of laboratory animals (Protocol ID number IS00000479).
Mouse Model of Angelman Syndrome
Mice with a UBE3A null mutation have been described previously. Female paternal
deficient mice (Jackson Labs, Bar Harbor, ME) were bred with C57BL/6 wild type male mice to
produce F1 generations of maternal deficient hybrid mice and wild type littermate controls as
previously described (Jiang, Armstrong et al. 1998). Animals were kept on a 12-hour light/dark
cycle and food and water was provided ad libitum. All experiments were performed during the
light cycle with each treatment group consisting of a minimum of seven male, 2-3 month old
animals.
General Activity
The open field test was used to measure activity. As previously described, mice were
allowed to explore a 40 x 40 cm acrylic chamber for 15 minutes (Daily, Nash et al. 2011). Behavior
was monitored via video tracking software (ANY-maze, Stoelting, Wood Dale, IL) and measures
of movement and distance traveled were recorded. As a measure of anxiety, the amount of time
spent in the center of the apparatus was compared to the amount of time spent in the perimeter
(along the walls). The elevated plus maze was also used to assess anxiety. The animals were placed
in a plus-shaped maze elevated 40 cm above the table top and consists of 2 open arms and 2 closed
arms. Each mouse was placed in the apparatus and allowed to explore for 5 minutes. Increased
time spent in the open arm over the closed arm indicates reduced anxiety.
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Motor Performance
The accelerating rotorod was used to assess motor coordination and motor learning (Ugo
Basile, Italy). As previously described, mice were placed on a 3 cm diameter rotating rod with an
initial speed of 4 RPM accelerating to 40 RPM over 300 seconds (van Woerden, Harris et al. 2007,
Daily, Nash et al. 2011). The latency to fall off the rod for each animal was recorded for 4 trials
over 2 consecutive days.
Associative Fear Conditioning
To assess hippocampal function and memory, mice were trained by placing the animals in
a 25 x 25 cm context with a wire grid floor surrounded by a sound attenuated chamber. They were
allowed to explore for 120 seconds prior to the initiation of the conditioned stimulus (CS), a 30second, 90db tone. After 28 seconds, the unconditioned stimulus (US), a 0.8mA foot shock, was
administered for 2 seconds. After a 90 second inter-stimulus interval, a second pairing was initiated
followed by another 90 second resting period before returning the animals to their housing.
Contextual fear conditioning was conducted 24 hours after the training in the same chamber with
no CS for 180 seconds. The amount of time the animal spent freezing was recorded by behavioral
monitoring software (ANY-maze, Stoelting, Wood Dale, IL). After the contextual trial, the
chamber was altered by the addition of a novel scent, floor texture and wall coverings. Cued fear
conditioning was carried out by allowing the mice to explore the novel context for 180 seconds
after which, a conditioned stimulus, identical to training, was introduced for another 180 seconds.
Freezing behavior was recorded during both periods of time using the same behavioral monitoring
software mentioned above. Freezing behavior was defined as immobility for a period of at least 2
seconds.
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In Vivo Dendritic Spine Analysis
After 28 days of minocycline injection, brains were harvested and bisected. One
hemisphere per animal was immersed in 1 ml per gram of tissue of Golgi impregnation solution
(Rapid Golgi Staining Kit, FD Neurotechnologies, Columbia, MD) and stored at room temperature
free from exposure to light. The impregnation solution was exchanged after 24 hours of immersion
and tissue was incubated for a period of 10 to 14 days. The brain tissue was transferred to solution
C for 72 hours. Each brain was then sectioned to a thickness of 100μm using a vibratome
(VT1000S, Leica, Buffalo Grove, IL) and mounted on gelatin-coated slides. After a drying period,
slides were rinsed in Milli-Q water, stained with a mixture of solution D and E, dehydrated and
cleared with xylene according to the manual. Coverslipping was achieved using undiluted
Permount (Fisher Scientific, Pittsburg, PA).
Using bright field microscopy (Axioplan 2, Zeiss, Pleasanton, CA), Z-stack images were
taken of 20 µm lengths of 2 apical dendrites of 10 area CA1 pyramidal neurons at 100x
magnification and analyzed using RECONSTRUCT software (http://synapses.clm.utexas.edu) as
described by Risher et al. for spine density and morphology by a blinded analyst (Risher,
Ustunkaya et al. 2014).
Hippocampal Slice Preparation and Electrophysiology
Euthanasia was achieved by rapid decapitation after which the brain was placed in ice-cold
cutting solution (110mM sucrose, 60mM NaCl, 28mM NaHCO3, 1.25mM NaH2Po4, 7mM MgCl2,
0.5mM CaCl2, 0.6mM sodium ascorbate, and 5mM D- glucose, pH 7.4). The brain was sectioned
horizontally into 400 μM slices and allowed to equilibrate in a mixture of 50% cutting and 50%
ACSF solution for 15 minutes. Slices were then transferred to artificial cerebral spinal fluid
(ACSF, 125mM NaCl, 2.5mM KCl, 1.25 NaH2PO4, 28 mM NaHCO3, 1.0 MgCl2, and 10 mM D25

glucose, pH 7.3) at room temperature for 30 minutes prior to placement in the interface chamber.
Supported by nylon mesh, slices were bathed in ACSF saturated with 95% O2 and 5% CO2.
As previously described by Weeber et al., pyramidal neurons of area CA3 were stimulated
with a bipolar electrode and recordings were obtained via glass microelectrode filled with ACSF
(1-4 mΩ resistance) from area CA1 pyramidal neurons. Theta-burst stimulation (TBS), 5 trains of
four pulses at 200Hz separated by 200 ms and repeated a total of 6 times with a 10 second intertrain
interval, were used to evoke CA1 long-term potentiation (LTP). Stimulus intensity was adjusted
so fEPSPs (field excitatory postsynaptic potentials) slopes were ≤50% of the maximum stimulus
intensity as determined from the input/output curve. Potentiation was measured as the increase in
the mean fEPSP following stimulation normalized to the mean fEPSP for the baseline recording.
Results were obtained from slices that exhibited a stable baseline for 20 minutes prior to the
stimulus delivery (Weeber, Beffert et al. 2002).
Results
Minocycline at Lower Dosage Improves Contextual Learning but not Motor Ability
To date, the activity level of naive AS mice has not been described. However, Daily et al.
shows similar amounts of activity between WT and AS transgenic mice (Daily, Nash et al. 2011).
Since hyper or hypo-active behavior can affect the results of behavioral testing such as fear
conditioning, general activity levels of these AS mice were assessed using the open field test. Mice
were placed in the center of a 40cm x 40cm acrylic chamber and allowed to explore freely for a
period of 15 minutes. The distance traveled by the animal is recorded by computer tracking
software (Anymaze, Stoelting, Wood Dale, IL). We observed no significant differences (F(5,59)
= 1.461, p = 0.218) in the distance traveled between either genotype or treatment groups (Figure
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2-3). These results suggest minocycline does not affect the overall activity of these mice and any
subsequent behavioral differences are not the result of hyper- or hypo-activity.

Distance Traveled (m)

OPEN FIELD TESTING
40
30
20
10
0

WT

AS

SAL

45MG

22.5MG

Figure 2-3. Similar Amounts of Activity was Observed Between
Genotypes and Treatment Groups.
No significant differences between any groups were observed in the
mean distance traveled during 15 minutes of open exploration. These
data suggest the activity level for all groups is similar and results of
other behavioral tests are not affected by hypo or hyper-activity.
Patients with AS often exhibit tremor, ataxia and general motor incoordination. Similarly,
UBE3A maternal deficient (AS) mice have been shown to exhibit deficits in motor ability evident
by shorter latency to fall times when compared to wildtype (WT) mice (Jiang, Armstrong et al.
1998). To test the effect of minocycline on motor function, 2 cohorts (22.5 and 45 mg/kg dosage)
of 4 treatment groups (WT, WT treated, AS and AS treated) where subject to the rotorod test (Ugo
Basile, Varese, Italy). All groups exhibited improvement in latency to fall over 8 trials which is
evidence of intact motor learning (Figure 2-4). However, between group comparisons revealed
significant differences, F(3,31) = 6.248, p = 0.0022, existed only between genotypes (AS and WT)
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and a treatment effect was not observed. These results suggest that while motor learning remains
intact after receiving minocycline treatment, treatment with the antibiotic does not improve the
motor coordination of these AS mice.
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Figure 2-4. Treatment with Minocycline Does Not Improve Motor Performance on the
Accelerating Rotating Rod.
A minimum of eight animals per group were tested on the accelerating rotating rod in two
cohorts, those animals receiving a 45mg/kg or 22.5mg/kg dose (IP injection) with WT
littermates receiving saline injections as a control. As expected, AS mice had significantly
shorter latency to fall times than WT animals. Moreover, increases in latency to fall times
were not observed after treatment with either dosage of minocycline.
In addition to motor disability, patients with AS also exhibit deficits in learning ability. To
test the effect of minocycline on associative learning, AS and WT mice were subject to the fear
conditioning paradigm. Fear conditioning is a form of associative learning in many species of
animals and consists of two distinct forms of learning, contextual and cued. During cued fear
conditioning, the animal is presented with an auditory stimulus just prior to an aversive stimulus
(a foot shock). The association of the auditory stimulus with the aversive stimulus has been shown
to be resistant to hippocampal lessoning. A fear response, in the form of a motionless, crouching
posture (freezing) was assessed for 3 minutes in the original context using computer tracking
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software (Anymaze, Stoelting, Wood Dale, IL). In this experiment, freezing behavior was assessed
for 6 minutes (3 minutes of silence followed by 3 minutes of tone) in a neutral context. We
observed no differences in freezing either between genotypes or treatment groups in these 2
cohorts.
During contextual learning
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Figure 2-5. Minocycline Treatment Significantly
Increased the Amount of Freezing in AS Mice.

45mg/kg of minocycline (Figure 25). However, AS mice treated with
the lower dosage of minocycline

A) No significant differences were observed between
groups when mice were treated with 45mg/kg of
minocycline. B) A significant increase in freezing
(F(3,27) = 3.717, p = 0.025) was observed in AS mice
that received 22.5 mg/kg of minocycline when
compared to those receiving saline.
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exhibited a significant increase in
freezing (F(3,27) = 3.717, p = 0.025)
as compared to AS mice receiving

saline when placed back into the training context. These results suggest minocycline does not have
an effect in animals with intact contextual learning. However, the deficits in hippocampal
dependent learning associated with the AS mouse can be overcome after treatment with 22.5mg/kg
of minocycline but not 45mg/kg. This suggests a non-linear relationship exists between dosage
and the effects on hippocampal dependent learning.
Treatment with Minocycline Results in Increased LTP Response of CA1 Pyramidal Neurons
Hippocampal LTP is a well established method of measuring synaptic plasticity. Severe
deficits in LTP of the CA1 pyramidal neurons after high-frequency stimulation have previously
been shown in the maternal deficient AS mouse model (Jiang, Armstrong et al. 1998, Weeber,
Jiang et al. 2003, van Woerden, Harris et al. 2007, Daily, Nash et al. 2011, Filonova, Trotter et al.
2014, Grieco, Ciarlone et al. 2014, Hethorn, Ciarlone et al. 2015). We recorded
electrophysiological responses (Figure 2-6) from neurons in area CA1 to determine if changes in
synaptic function existed in conjunction with the observed changes in freezing behavior after
treatment with minocycline. The input/output relationship was evaluated by comparing fEPSP
slope to fiber volley (FV) amplitude across a range of stimulus intensities, from 1 to 15 mV.
Omnibus ANOVA and Tukey’s post hoc test results revealed statistically significant (F(3,106) =
3.688, p = 0.0144) differences both WT and AS mice that had received 45mg/kg of minocycline
and mice receiving saline vehicle injections (Figure 2-6A). When the FV and fEPSP slope was
compared to the stimulation intensity separately, a significant increase (F(3, 115) = 2.919, p =
0.0372) in presynaptic activation (Figure 2-6B) was observed in AS control mice (saline vehicle
injected). Moreover, a significant decrease (F(3,115) = 6.737, p = 0.0003) in post-synaptic
activation (Figure 2-6C) was observed for both AS and WT mice treated with minocycline
compared to mice treated with saline vehicle. A paired
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Figure 2-6. The Administration of Minocycline Alters the Postsynaptic Response to
Stimulus and Results in Increased LTP.
A) Input/output was evaluated by comparing fEPSP slope to fiber volley (FV) amplitude across a range of
stimulus intensities (1-15 mV). Statistical analysis revealed a significant, F(3,106) = 6.314, P = 0.0144)
difference between the WT and AS mice that had received 45mg/kg of minocycline and those that had received
saline, but not between genotypes. B & C) The FV amplitude and fEPSP slope were then compared to the
stimulus intensities separately and revealed a significant, F(3,115)) = 2.919, p = 0.0372 and F(3,115) = 6.737,
p = 0.0003 respectively, difference in presynaptic activation in the AS mice receiving saline when compared
to all (WT, WT MC, AS MC) of the other groups. Moreover, postsynaptic activation was reduced when both
WT and AS mice received treatment with minocycline. D) A paired-pulse facilitation protocol (20-300ms) was
used test short-term presynaptic plasticity and revealed no significant differences between any of the groups.
E) LTP was induced using a theta-burst stimulation protocol. Significant reductions (F(2,259) =7.719, p =
0.0006) in the induction of LTP was observed in the slices of AS mice receiving saline treatment. However,
slices from AS mice treated with of minocycline showed an increase in LTP, to the level of WT, resulting in
the recovery of the LTP deficit associated with these AS mice. F) Slices from WT animals treated with 45mg/kg
of minocycline did not show a significant increase in LTP over WT mice treated with saline.
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pulse facilitation protocol (20 to 300ms) was used to test short-term presynaptic plasticity and no
significant differences (Figure 2-6D) was seen between any of the groups. These results suggest
pre-synaptic hyperactivity may contribute to the synaptic dysfunction observed in the AS mouse
model. Further, the pre and post-synaptic response to stimulus can be attenuated with the
administration of minocycline.
LTP was induced using our previously described TBS stimulation. Consistent with
previously published results, we found that AS mice receiving saline treatment exhibited
significant deficits in high frequency stimulation (HFS) induced LTP when compared to WT
littermate controls (Figure 2-6E & F). Interestingly, we found both treatment groups, WT MC and
AS MC, exhibited LTP measures that significantly (F(3,339) = 31.79, p <0.0001) exceed those of
the AS control mice and restored the LTP measures of AS treated mice to the level of WT controls
after TBS.
Minocycline Recovers the Dendritic Spine Density Defect in the AS Mouse Model
Many forms of severe cognitive impairment have been tied to pathologic alterations in
dendritic spine structure and distribution (Smrt and Zhao 2010). For example, previous AS
research shows AS mice exhibit reduced dendritic spine density in area CA1 as well as layer 3-5
pyramidal neurons. This pathology underlies the aberrant synaptic function observed in the AS
mouse model (Dindot, Antalffy et al. 2008, Hethorn, Ciarlone et al. 2015). However, when spine
density is restored, a recovery of associative fear conditioning and synaptic plasticity deficits is
observed (Hethorn, Ciarlone et al. 2015). Consistent with previous research, histologic analysis of
the apical dendrites from CA1 area Golgi impregnated pyramidal neurons of these mice reveal a
significant reduction (F(5,38) = 5.538, p = 0.0008) in the spine density of AS mice when compared
to WT littermate controls (Figure 2-7A & B). Interestingly, the treatment of AS mice with either
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Figure 2-7. Minocycline Treatment Increases the Mean Density of Dendritic Spines in the
AS Mouse.
A) Light micrograph images from Golgi impregnated hippocampal pyramidal neuron from WT
and AS mice treated with saline, 22.5 and 45mg/kg of minocycline (Scale bar = 10µm). B)
Quantification of the dendritic spines of apical dendrites of pyramidal neurons located in area
CA1 of the hippocampus. The spine density of saline vehicle treated mice is significantly reduced
compared to WT saline treated animals. Both treatments, 22.5 and 45mg/kg of minocycline,
rescued the spine density deficit of the AS mouse (F(5,38) = 5.538, P = 0.0008). C) Significant
increase in the total number of mushroom shaped (mature) dendritic spines was observed in WT
mice treated with 45mg/kg of minocycline (F(5,38) = 3.687, p = 0.0092).
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22.5 or 45mg/kg of minocycline rescued the defect by significantly increasing (F(5,38) = 5.538, p
= 0.0008) the mean spine density to the level of their WT littermates. This suggests minocycline
may increase dendritic spine density and therefore the number of functional and/or active synapses.
Because of the role dendritic spines play in synaptic function, altered spine morphology
has a significant impact on the function of the neural network as a whole (Smrt and Zhao 2010).
For instance, abnormal spine morphology has been observed in several conditions such as autism,
Rett and Fragile X syndromes. To determine minocycline’s effect on spine morphology, we used
the rapid analysis method described by Risher et al. and the freely available software,
RECONSTRUCT (http://synapses.clm.utexas.edu), to analyze the apical dendrites from CA1 area
Golgi impregnated pyramidal neurons of these mice (Risher, Ustunkaya et al. 2014). Results of
our analysis reveal no significant differences in the morphology of the animals examined (n = 5
mice per group, 20 neurons per group, 2 apical dendrites per neuron) with one exception. A
significant increase in mushroom shaped (mature) spines was observed (Figure 2-7C) when WT
animals were treated with 45mg/kg of minocycline. These data suggest minocycline may have
ability to influence the development of more mature synapses (mushroom shaped spines) resulting
in improvements in synaptic function.
Discussion
Defects in synaptic plasticity caused by the lack of a functioning UBE3A protein has been
suggested as the core cause of impairment in the AS mouse. Unfortunately, histologic study of the
brain from 1 human female with AS revealed alteration in the morphology and density of dendritic
spines (Jay, Becker et al. 1991). However, this does provide supportive evidence that aberrant
synaptic function is the underlying cause of the learning deficits associated with AS in humans
and mice. Factors that contribute to proper synaptic function include, but are not limited to, the
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structure and morphology of dendritic spines, the transmission of neurotransmitter, the density and
function of glutamate receptors (AMPA and NMDA).
Results of our behavioral testing show that while the activity level of each genotype and
treatment group was similar, the AS mice treated with a lower dose (22.5mg/kg) of minocycline
showed greater associative learning than saline vehicle controls. Integration of sensory cues
combined with somatosensory processing via the hippocampus suggest that a global increase in
synaptic function is likely to contribute to the correction of the associative learning defect. Further
support is provided by increased LTP in AS mice.
In hippocampal primary cell culture from mice with Fragile X, normalization of morphology,
from filopodial to mushroom shaped, was reported when minocycline was applied (Bilousova,
Dansie et al. 2009). Many have shown the cellular basis of learning and memory requires the
dendritic spines of pyramidal neurons to undergo structural remodeling. While the relationship
between remodeling and plasticity, such as LTP, has not yet been determined, most agree the
normalization of dendritic spine density results in increased LTP (Yuste and Bonhoeffer 2001,
Matsuzaki, Honkura et al. 2004). Consistent with the results of Bilosova et al., histological analysis
of Golgi impregnated hippocampal slices of these AS mice revealed a dramatic reduction in the
mean density of dendritic spines of area CA1 pyramidal apical dendrites when AS mice were
compared to WT mice. Further, when AS mice were treated with either 22.5 or 45mg/kg of
minocycline, a complete recovery of the spine deficit was observed. To assess the spine
morphology in these AS mice, we used computer software to measure the length and width of
spines and saw no differences in the total number of any one specific morphology (mushroom,
filopodial, long thin, thin, stubby or branched) between groups.
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These data suggest the observed changes in behavior (increased freezing time) may be due to a
normalization of the overall dendritic spine density rather than a change from one spine
morphology to another in the area CA1 pyramidal neurons of these AS mice.
Interestingly, minocycline has been shown to chelate Ca2+, inhibit NMDA-induced cytosolic
Ca2+ concentrations and, in the presence of Ca2+, deprotonated minocycline may form membrane
bound ion channels (Antonenko, Rokitskaya et al. 2010, Garcia-Martinez, Sanz-Blasco et al.
2010). Moreover, Gonzalez et al. report a 20% and 30% decrease in inward Na+ and Ca2+ current
in cultured rat hippocampal neurons. Also, glutamate-evoked elevations of Ca2+ were reduced by
40% at high but not low concentrations of minocycline (González, Egea et al. 2007). These reports
suggest that minocycline alters the membrane potential, which may result in hyperpolarization of
the neuron. While the exact mechanism is still unknown, these reports provide a possible
explanation for the significant decrease in FV amplitude and fEPSP slope observed in these AS
mice when treated with the higher dose of the drug. This may also underlie the increase variation
in AS mice treated with 45mg/kg of minocycline.
Conclusion
Minocycline is a widely used antibiotic medication with a long history of safety and
tolerability in humans. Several studies have shown the drug to improve learning and memory and
protect neurons from excitotoxicity. We show the treatment of AS mice with minocycline results
in normalization of dendritic spine density as well as an increase in LTP. While a specific
mechanism is unknown, these effects provide a potential explanation for a dose dependent increase
in associative learning in the AS mouse model. These results show the promise of minocycline for
use as a potential therapeutic for Angelman syndrome.
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CHAPTER 3

MINOCYCLINE TREATMENT IS WELL TOLERATED AND IMPROVES ADAPTIVE
BEHAVIORS IN CHILDREN WITH ANGELMAN SYNDROME
Background
Consistent with the initial description by Dr. Harry Angelman, children with AS present
clinically with physical features such as microcephaly and a puppet like gait as wells as profound
developmental delays and little vocal communication ability (Angelman 1965, Barry, Leitner et
al. 2005, Williams 2005, Horsler and Oliver 2006, Williams 2010). While these patients exhibit a
happy demeanor and easily provoked laughter, this syndrome also consists of other manifestations
including hyper-excitability, poor motor function, and delays in adaptive behaviors. Furthermore,
patients with AS exhibit EEG patterns specific to the syndrome, and when present in the
appropriate clinical context, help in diagnosing the syndrome earlier. Finally, 90% of children
diagnosed with AS suffer from seizure of various types and severity (Boyd, Harden et al. 1988,
Laan, Renier et al. 1997, Clayton-Smith and Laan 2003, Laan and Vein 2005, Williams 2005, Pelc,
Boyd et al. 2008, Pelc, Cheron et al. 2008, Vendrame, Loddenkemper et al. 2012, Vendrame,
Loddenkemper et al. 2012).
In nearly all cases Angelman syndrome results from the disruption of a single gene, UBE3A
(Kishino, Lalande et al. 1997, Williams 2009). Previous research in both the AS mouse model and
humans with AS show no gross morphology changes in the brain. However, the absence of the
protein product, UBE3A, a E3 ubiquitin ligase, results in the accumulation of regulatory proteins,
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such as arc and ephexin 5 in the postsynaptic density, which is believed to cause abnormal dendritic
spine morphology (filopodial) and density in hippocampal pyramidal neurons leading to aberrant
synaptic function (Scott, Barbara et al. 2007, Margolis, Salogiannis et al. 2010). These alterations
in spine morphology and synaptic function in neurons provides an explanation for the severe
behavioral and cognitive manifestations of the syndrome. Our laboratory has recently reported the
application of Reelin, a protein shown to increase dendritic spine density, enhanced cognition in a
mouse model (Rogers, Rusiana et al. 2011). Further, other researchers have recently reported the
recovery of the cognitive and behavioral deficits associated with AS and even the commencement
of UBE3A protein production when certain therapeutics such as UBE3A viral vectors and
topoisomerase inhibitors were applied (van Woerden, Harris et al. 2007, Daily, Nash et al. 2011,
Huang, Allen et al. 2012). It stands to reason then, a therapeutic with the ability to normalize the
aberrant synaptic function underlying AS could ameliorate the severity of symptoms.
Minocycline hydrochloride (MC) is a small (495 kDa), lipophilic, second-generation
tetracycline antibiotic medication that readily crosses the blood brain barrier (Ulgen, Field et al.
2011). These characteristics allow minocycline to penetrate the central nervous system more
readily than other members of the tetracycline family (Macdonald, Kelly et al. 1973). As with the
aforementioned therapies, minocycline has been shown to recover synaptic dysfunction through
the modulation of dendritic spine structure by reducing the activity of matrix metalloproteinases
(Bilousova, Dansie et al. 2009). Previous research has shown the incubation of neuronal cultures
with MMP-9 altered dendritic spine shape and number. Moreover, increases in both protein level
and activity of the MMP’s occurs in models of epilepsy, which is prevalent in the AS population
(Pelc, Boyd et al. 2008). Further, minocycline changes the morphology of dendritic spines in
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hippocampal neurons from elongated (immature) to mushroom-shaped (mature), ultimately
rescuing the synaptic defect and improving spatial memory (Bilousova, Dansie et al. 2009).
Interestingly the application of minocycline has been shown to act on numerous other
aspects of the CNS. The drug has been shown to be neuroprotective, anti-apoptotic, and antiinflammatory (Thomas and Huganir 2004, Kernt, Neubauer et al. 2010, Mehrotra, Pecaut et al.
2014). Beyond this, minocycline can positively alter the AMPA-type glutamate receptor (Chen
and Manev 2011, Jin, Schlesinger et al. 2012), metabotropic glutamate receptor 1 and 5 (Fujita,
Ishima et al. 2008, Greer, Hanayama et al. 2010) and NMDA receptor function (Goni-Allo, Ramos
et al. 2005, Greer, Hanayama et al. 2010). Metabotropic glutamate receptors, AMPA receptors and
NMDA receptors are known to be important in overall neuronal function and contribute to the
synaptic plasticity defect in the AS mouse model (Quinlan, Philpot et al. 1999, Weeber, Jiang et
al. 2003, Fujita, Ishima et al. 2008, Pignatelli, Piccinin et al. 2014).
Minocycline has also been used as a treatment of other human cognitive disorders. For
example, when MC was administered to patients with Fragile X syndrome (FRX), significant
behavioral improvement in the subscale scores of the Aberrant Behavior Checklist-Community,
as well as the Visual Analog Scale and Clinical Global Impressions Scale scores were reported
with only minor adverse effects observed (Paribello, Tao et al. 2010). Studies of the drug’s effect
on degenerative neuropathology (e.g., Alzheimer’s and Parkinson’s disease, Amyotrophic Lateral
Sclerosis) have shown the administration of minocycline reduces the severity and progression of
disease and, in some cases, prolongs the lifespan of animal models (Yong, Wells et al. 2004,
Garrido-Mesa, Zarzuelo et al. 2013).
Preclinical electrophysiological studies were carried out in a mouse model of AS
(RRID:IMSR_JAX:004477) after 21 days of minocycline treatment. We found a full recovery of
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the synaptic plasticity defect normally observed in the AS mouse model (Figure 3-1) (van
Woerden, Harris et al. 2007). We, and others, have shown a reduction in synaptic plasticity in the
hippocampus, cerebellum and visual cortex in the AS mice (Quinlan, Philpot et al. 1999, Weeber,
Jiang et al. 2003, Egawa, Kitagawa et al. 2012). Therefore, recovery of the synaptic plasticity
defect was a significant finding for this therapeutic.
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Figure 3-1. Minocycline Restores the Synaptic Plasticity Defect in the AS Mouse
Model.
3-month-old UBE3A maternal deficient (AS) mice (129Sv/Ev background) show
increase in long-term potentiation (LTP) after 21 days of treatment with minocycline.
Field extracellular postsynaptic potentials (fEPSPs) were recorded and their slopes are
conveyed as a percentage of the pre-theta burst stimulation (TBS) baseline.
Representative traces before (bold) and 30 minutes after TBS are shown for saline treated
(control) and minocycline treated AS mice.
The precise mechanism of minocycline, beyond its antibacterial mechanism, is unknown.
However, this has not precluded the investigation of minocycline (with associated benefit) on
human neurological diseases such as Alzheimer’s, Parkinson’s, Stroke, traumatic brain injuries
and Fragile X syndrome (Yong, Wells et al. 2004, Paribello, Tao et al. 2010, Garrido-Mesa,
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Zarzuelo et al. 2013). The results of the above mentioned studies led us to posit that administering
minocycline to patients with Angelman syndrome may ameliorate the central nervous system
symptoms associated with the syndrome and improve behavioral performance. Here, we report the
changes in symptom severity, cognition, and adaptive behavior after a sample of 25 children with
Angelman syndrome were administered minocycline for 8 weeks. The objective of this study was
to evaluate the tolerability of minocycline in children with AS and provide preliminary
neuropsychological and electroneurophysiology data.
Methods
Study Design
This study took place at the University of South Florida and was approved by USF’s
Human Research Protection Program’s Institutional Review Board (Pro00004716). The USF IRB
issued a waiver of assent; however written informed consent was obtained from both the mother
and father of each participant. Since no previous research existed showing how children with AS
would respond to minocycline, statistical methods could not be employed to determine sample
size. Therefore, human subject protections mandated a single arm open-label study design be
implemented with no placebo control. After baseline testing (T1), 25 children with AS were
prescribed minocycline for 8 weeks. No change in the participant’s medication regimen was
required for inclusion in the trial. The time course and dosing was determined from previous
research in which children with FRX were administered minocycline (Paribello, Tao et al. 2010).
The study participants were evaluated again after 8 weeks of treatment (T2) and 8 weeks after
minocycline was discontinued (T3).
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Recruitment
Participants of this study were recruited through the websites of Angelman parent
organizations and clinicaltrials.gov. Children with Angelman syndrome, who met the inclusion/
exclusion criteria were pooled and participants were selected at random using a computer
generated randomization schedule (SAS, Cary, NC). To minimize the chance of screen failure,
parents were required to have their child’s primary care provider or neurologist complete a short
questionnaire attesting the child met the inclusion criteria and provide an indication of the severity
of the child’s disability due to Angelman syndrome. Inclusion criteria included: 1) A molecularly
confirmed diagnosis of Angelman syndrome. 2) Age between 4 to 12 years old at the time of
recruitment. 3) A CGI-S score of 4 or greater indicating at least moderate severity of symptoms.
4) An acceptable surrogate capable of providing consent on the participant’s behalf.
Exclusion criteria included: 1) A known allergy to minocycline or any tetracycline. 2) No
molecular confirmation of the AS diagnosis. 3) Participation in another study in which a drug,
vitamin or dietary manipulation was used to treat AS within 6 months preceding enrollment. 4)
Severe or uncontrolled seizures or another medical condition(s) rendering the child medically
unstable. 5) A history of cardiovascular, respiratory, liver, kidney or hematologic disease or a
history of systemic lupus erythematosus.
Medical and Neuropsychological Evaluation
Each participant underwent 3 identical study visits consisting of medical evaluation and
neuropsychological examination at baseline, after 8 weeks of treatment with minocycline, and 8
weeks after the drug was discontinued. A board-certified pediatric neurologist completed a detailed
history and physical examination, assigned a Clinical Global Impressions – Severity (CGI-S) score
and interpreted the results of laboratory testing. As a safety measure, a complete blood count
42

(CBC), as well as blood urea nitrogen (BUN), creatinine, alanine amino transferase (ALT), and
aspartate aminotransferase (AST) levels was obtained at each time point to ensure proper function
of multiple organ systems. A routine 30-minute electroencephalogram completed the medical
evaluation. Neuropsychological measures were administered during each study visit. These
outcome measures included the Bayley Scales of Infant and Toddler Development 3rd Edition
(BSID-III), Vineland Adaptive Behavior Scales, 2nd Edition (Vinland-II), and Preschool
Language Scale, 4th Edition (PLS-IV). To ensure compliance with the dosing regimen, caregivers
were asked to record the date and time each dose of minocycline was administered.
Safety and Adverse Event Monitoring
Prior to the initiation of any study procedures both parents (or a legally authorized
representative) of participants were required to sign an informed consent document in person. The
document detailed all of the study procedures and each of the known side effects of minocycline.
During the course of the study, caregivers were asked to report any observed side effects and/or
changes in behavior immediately via telephone. After 4 and 8-weeks of minocycline treatment as
well as 4 and 8-weeks after the drug was discontinued caregivers were asked to complete online
questionnaires to document adherence to the medication regimen and to document any observation
the caregiver may have made. To assess the safety of minocycline on multiple organ systems, the
aforementioned blood-screening tests were reviewed during each study visit. When an adverse
event was reported, the duration, severity, relatedness and treatment status were documented
(Table 3-1).
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Table 3-1. A Summary of Adverse Events
Participant

Description of symptoms

1
2
3
4
5
8
10
11
13

Feminine Yeast Infection
Seizure - Atypical Absence
Commencement of Menstruation
Difficulty Standing & Balancing
Dark Spots on Shins
Lethargy/Sleepiness
Sleepiness
Diagnosis of Lyme Disease
Urinary Tract Infection
Seizure - Tonic-Clonic & Difficulty
15
Ambulating
21
Influenza Type A
22
Sleepiness and Difficulty Ambulating
24
Seizure
25
Seizure Associated with Fever & Vomiting
a
Adverse event occurred during minocycline treatment.
b
Participant required a dose adjustment.
c
Subject withdrew due to adverse event.

Latency to onset
(Days)
24a
56a
27a
63
18a
18a,b
20a,b
112
57
9a
57
39a,b
110c
113

Minocycline Dosing
After baseline testing, each subject was prescribed minocycline according to his or her
body weight (3 mg/kg/day, not exceeding 200 mg a day). The drug was dispensed in 50 mg caplets
to be taken orally twice daily (BID). While the lack of speech made it difficult to discern, 3
participants taking 200 mg per day appeared to suffer from intolerable lethargy and/or dizziness
(Table 3-1). The adverse effects resolved when the dose was reduced to 100 mg daily. The dosages
used here are equivalent to those used in clinical practice for children greater than 8 years of age
and have been established as tolerable and safe in similar patient populations (Fanning, Gump et
al. 1977, Goulden, Glass et al. 1996).
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Statistical Analysis
For each dependent measure, the effect of minocycline treatment was assessed using
repeated measures analysis of variance (ANOVA) with P values of less than 0.05 considered
significant. Post hoc Dunnett’s tests were performed to isolate significant changes from baseline
assessment values. A 2 x 3 mixed factor ANOVA was performed with age (≤9 or >9 years old) as
a between groups measure and assessment time as a repeated measure. For all analyses, partial η2
(effect size) was calculated according to the guidelines of Cohen (0.01 = small effect, 0.06 =
moderate effect, 0.14 = large effect) (Cohen 2013).
Primary Outcome Measure
Bayley Scales of Infant and Toddler Development, 3rd Edition was administered consistent
to the test manual, under the direct supervision of a board-certified neuropsychologist, and by a
single pyschometrician who was blind to the purpose and phase of the study. The BSID-III is a
measure of development used to assess the cognitive, language and motor abilities of children ages
1 to 42 months. The BSID-III yields scores for five developmental domains: Adaptive Behavior
(self-care and self-direction), Cognitive (attention, memory, sensorimotor, and visual preference),
Language (receptive and expressive language functions), Motor (fine and gross motor) and SocialEmotional (using emotional signals for self-regulation and communication needs). Internal
reliability of the BSID-III is high, ranging from α = 0.086 to 0.93 in healthy subjects. We chose to
administer this test because: 1) it has been shown to be reliable and valid with high correlation
coefficients for test-retest reliability in children with other neuropathologies (Black and Matula
2000); 2) the BSID-III is a common data element suggested by the National Institutes of Health
(NINDS) for clinical research involving children with Epilepsy, stroke and other neurologic
disorders (N.I.H. 2014); and 3) literature suggests the BSID-III is an appropriate neurocognitive
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measure to use in children, such as those with AS, that exhibit profound developmental delays
(DeWitt, Schreck et al. 1998, Peters, Goddard-Finegold et al. 2004, Peters, Bird et al. 2010). Under
normal circumstances raw scores are converted to standard scores based on age-matched healthy
normative data. Children in this sample exhibited raw scores that were well below age-matched
peers’ performances, which would result in standard scores at the floor of the distribution. Past
research using the BSID-II in children with AS reported raw scores (Peters, Goddard-Finegold et
al. 2004). Moreover, reporting raw scores adheres to the STROBE reporting guidelines (Loring
and Bowden 2014). Finally, utilizing raw scores may better reflect clinical change in functional
ability that could be observed for children with profound neurocognitive deficits (e.g., increase in
the number of spoken words, or initial expression of speech) that remains far below expectations
for age-matched healthy peers and not reflected in standardized scores. Therefore, this study
employed raw scores to provide a quantitative assessment of skills and abilities of the BSID-III
domains in our analyses (Peters, Goddard-Finegold et al. 2004, Education 2008).
Secondary Outcome Measures
The secondary outcome measures include the Vineland Adaptive Behavior Scales 2nd
Edition (VABS-II) and the Preschool Language Scale 4th Edition (PLS-IV). The VABS-II is a
designated NIH common data element for assessment of adaptive skills across 4 behavioral
domains: Communication, Daily living skills, Socialization, Motor ability and also assesses
maladaptive behaviors. Scores are based on subjective ratings of parent’s/primary care provider’s
perception of a child’s ability to complete various behaviors/tasks. The VABS-II was designed for
special needs children, including those with intellectual disabilities, autistic spectrum disorders
and ADHD. The test provides normative data for individuals from birth to age 90 years old.
Internal reliability for early childhood, birth through 36 months, is α = 0.79 to 0.95 and varied
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from α = 0.83 to 0.93 for children aged 4 to 5 years old. Inter-rater reliability of two different
caregivers for the same individual aged birth to 6 years old were moderate to large, ranging from
α = 0.61 to 0.82. (Peters, Bird et al. 2010, Loring, Lowenstein et al. 2011, Thibert, Pfeifer et al.
2012). The PLS-IV is well-recognized interactive and comprehensive assessment of
developmental language for children aged birth to 7 years, 11 months of age. Assessment provides
scores for Total language ability, Auditory Comprehension and Expressive Communication.
Internal reliability of measures are generally high, ranging from α = 0.80 to 0.97. Both the
Vineland-II and the PLS-IV have been used extensively in research evaluating developmental
language deficits across a variety of developmental disabilities, including Angelman syndrome
(Bird, Tan et al. 2011).
Clinical Assessment
A physical examination and EEG assessment was performed at baseline (T1), after 8 weeks of
minocycline treatment (T2) and after an 8-week washout period (T3). At every time point, a boardcertified pediatric neurologist utilized the clinical global impressions severity scale to rate the
severity of the participant’s condition, where 0 represents no symptoms and 7 the most severe
symptoms. This scale provides a quantitative measure of symptom severity that allows the
clinician to take into account the participant’s history, symptoms, behavior and how his or her
disability impacted daily living before and after treatment (Busner and Targum 2007).
A routine 21-channel EEG study was performed utilizing a standard 10/20 system of
electrode placement. 30 to 60 minute EEG recordings in the awake and, whenever possible, asleep
states were obtained without sedation. After the conclusion of the study, each EEG recording was
de-identified, and placed in random order so that the EEG order and relation to treatment were not
known. A scoring system was used to evaluate several aspects of the EEG recordings regardless
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of whether or not they were a part of AS specific EEG patterns. Points were assigned when a
particular characteristic was observed. For example, 1 point was given if an EEG was abnormal
overall. Characteristics that would be considered more abnormal were scored accordingly. For
instance, when evaluating the EEG background, 1 point was assigned if primarily theta waves
(mild slowing, >50%) were observed. When a mixture of theta and delta waves (moderate slowing)
were observed, 2 points were assigned. When primarily delta waves (severe slowing, >50%) were
recorded 3 points were assigned. Other EEG characteristics were also examined including occipital
rhythm (normal-1, slow-2 and absent-3), rhythmic theta (present <50% of the time-1, present
>50% of the time-2), rhythmic delta (present-3) and epileptiform abnormalities (present-1, focal1, multifocal-1, generalized-1, seizure-2). The points were totaled resulting in a total score, ranging
from 0 (most normal) to 24 (most abnormal).
Results
Study Participants: 11 female and 14 male children, mean age 8.2 years old, were enrolled
in the study. Of those enrolled, 21 participants were confirmed to have a maternal deletion (the
number of deleted bases was variable) and 4 were positive for a mutation of the UBE3A gene.
Twenty-four children completed the 16-week open-label study; one participant withdrew at week
16 due to unrelated seizure activity.
Primary Outcome Measure
A significant improvement in raw scores of the communication subscale of Bayley-III
(Table 3-2) was observed at T3 when compared to T1, F(2,46) = 3.72, p < 0.05. Post hoc analysis
revealed scores from participants between the ages of 4 and 9 years old were responsible for a 40%
increase, while scores from participants between ages 9 and 12 years of age remained unchanged.
Moreover, a significant improvement, F(2,46) = 5.011, p < 0.05, of the subscale self-direction was
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observed at both T2 and T3 compared to T1. While no change was observed in gross motor ability,
a significant increase (15%) in the measure of fine motor ability was observed at T3 when
compared to T2, F(2,46) = 3.28, p < 0.05.
Neuropsychological Outcomes
A significant improvement in the raw scores of the receptive communication index of the
Vineland-II was found between T2 and T1, F(2,46) = 6.73, p < 0.05. Two domains of the PLS-IV,
auditory comprehension and total language ability, were both found to have increased significantly
when measures at T3 were compared to T1, F(2,44) = 6.73, p <0.05 and F(2,44) = 5.84, p <0.05,
respectively.
Table 3-2. Neuropsychological Outcome Measures
Bayley Scales of Infant and Toddler Development, 3rd Edition

T1
T2
T3
η2

Cognitive

Communication

26.4 ± 2.48
31.7 ± 1.83
30.7 ± 2.09
0.05

18.9 ± 1.60
22.8 ± 1.69
*23.5 ± 1.88
0.05

Language

Motor

Self

Receptive

Expressive

Gross

Fine

Care

Direction

13.4 ± 0.61
13.7 ± 0.81
13.8 ± 0.68
0.002

10.1 ± 0.76
11.8 ± 0.75
11.2 ± 0.68
0.04

41.3 ± 1.69
40.5 ± 1.60
42.8 ± 1.12
0.02

19.4 ± 1.05
19.8 ± 1.47
†
22.4 ± 1.5
0.03

37.8 ± 1.81
40.6 ± 1.84
40.0 ± 1.99
0.02

33.8 ± 2.24
*38.1 ± 1.98
*39.5 ± 1.94
0.06

Vineland Adaptive Behavior Scales, 2nd Edition
T1
T2
T3
η2

Maladaptive Behavior
Internal
External

Communication
Receptive
Expressive

6.7 ± 0.44
5.5 ± 0.47
5.7 ± 0.52
0.05

30.3 ± 1.62
*36.4 ± 2.42
33.9 ± 2.25
0.06

5.5 ± 0.58
4.7 ± 0.57
6.0 ± 1.25
0.02

41.8 ± 3.02
44.3 ± 3.23
43.8 ± 2.58
0.06

Motor
Gross
Fine
48.3 ± 3.27
48.9 ± 3.32
49.4 ± 3.25
0.001

99.0 ± 7.12
101.2 ± 7.5
95.4 ± 7.84
0.004

Daily Living Skills
Personal Domestic
53.8 ± 5.61
59.1 ± 5.75
56.4 ± 4.95
0.007

2.6 ± 0.95
3.8 ± 1.49
2.7 ± 0.92
0.01

Preschool Language Scale
T1
T2
T3
η2

Auditory Comprehension

Total Language

Expressive Communication

17.64 ± 0.68
18.25 ± 0.58
*20.48 ± 0.71
0.13

34.20 ± 1.58
34.88 ± 1.36
*38.83 ± 1.34
0.08

16.3 ± 1.14
16.6 ± 0.94
17.5 ± 0.71
0.001

Mean ± Standard Error.
η2 (Partial Eta squared) is a measure of effect size. 0.01 suggests a small effect, 0.06 a medium effect and 0.14 a large effect.
* p < 0.05 when the time point is compared to T1 (baseline).
† p < 0.05 when the time point is compared to T2 (after treatment with minocycline).
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Clinical Outcomes
Blood screening tests showed no clinically significant changes over the 16-week study
course and no serious adverse effects related to minocycline treatment were reported (Table 3-1).
In 3 cases, caregivers reported lethargy and/or dizziness that required a dose adjustment and was
considered related to the minocycline treatment. All of these participants were receiving 100 mg
of minocycline BID. In 2 other cases, caregivers reported difficultly standing and/or walking that
resolved after the discontinuation of minocycline. A significant clinical improvement over T1, for
all participants, as measured by the CGI-S score (Table 3-3), was observed at T2 and T3 [F(2, 46)
=13.20, p < 0.05]. Analysis of EEG scores revealed a 4.3% and 10.8% improvement when T2 and
T3 observations were compared to baseline but did not reach the level of significance [F(2,46) =
1.494, p > 0.05]. For both measures, calculated partial η2 was equal to 0.05, an indication of a
moderate effect size.

Table 3-3. Patient Populations & Clinical Measures
CGI
T1

Mean ±
Standard Deviation
Standard Error of the Mean
η2

T2

EEG
T3

T1

T2

T3

5.56 ±1.12 *4.96 ±1.10 *5.08 ±1.25 9.16 ±3.47 8.76 ±2.80 8.16 ±3.47
0.224

0.220
0.050

0.255

0.694

0.561

0.709

0.050

η2 (Partial Eta squared) is a measure of effect size. 0.01 suggests a small effect, 0.06 a medium
effect and 0.14 a large effect.
* Indicates p < 0.05 when the time point is compared to T1 (baseline).
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Discussion
To our knowledge, this is the first prospective trial of minocycline treatment in which
safety, tolerability, cognitive function and adaptive behavior were evaluated among children with
Angelman syndrome. Statistically significant changes were observed across several subscales with
moderate relative effect sizes (Table 3-2) in both the primary and secondary outcome measures
when language ability and self-direction at T2 and T3 was compared to T1 and communication
skills at T3 was compared to T1. When the mean scores for all participants were analyzed, a
significant improvement in communication and fine motor ability was observed. Participants also
showed a significant improvement in self-direction, the ability to entertain themselves and follow
simple directions, after being treated with minocycline. This suggests minocycline may have
positive effects on aspects of the central nervous system resulting in improvements in language,
fine motor skills and some adaptive behaviors. While raw scores had to be used considering the
cognitive and language deficits of these children, the improvements in cognition, language and
motor skills were perceived by caregivers as shown by the VABS-II results. These pilot data show
minocycline may improve the pervasive cognitive and language deficits of these patients over a
16-week period.
The effects of minocycline were also observed clinically as shown by clinician rated
function (CGI-S) scores. No significant change in the EEG scores was observed. However, this
was measured with consistent anti-seizure medication and concurrent treatment of minocycline.
Thus, it is unclear whether minocycline has an effect on EEG patterns of AS patients not receiving
treatment for seizure. Caregivers reported few adverse effects and no severe adverse events related
to minocycline treatment. Language limitations required adverse event reports from caregivers
rather than participants themselves. In 3 cases, lethargy and/or dizziness was reported in
participants taking 200 mg of minocycline daily. These symptoms subsided after the dosage was
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reduced, suggesting a smaller dosage may be required to mitigate adverse effects. We show
statistically significant results after MC treatment was discontinued (T3) suggesting a lasting
treatment effect or persistent placebo effect. The optimal treatment course may be more extensive.
Therefore, further study is needed to determine the optimal length of treatment and what effect
extended exposure to minocycline may have in the AS patient population. In general, these data
suggest the short-term use of minocycline at these dosages in children with AS is well tolerated.
Several notable limitations of this pilot study include the behavioral manifestations of the
participants, single arm study design, lack of control for practice effect, and small sample size. As
expected, the behavioral characteristics of the participants (low tolerance for frustration, limited
language skills, articulation patterns that made speech intelligible only to caregivers) interfered
with their performance on the neuropsychological instruments. However, these behavioral deficits
reflect the severe cognitive and language impairments of these individuals and account for their
below age level skills in self-care and social behaviors. Moreover, the preponderance of the testing
consists of questionnaires and relies on parent responses that may include bias. Regardless, we
chose to employ the same neuropsychological instruments used in previous studies of AS patients.
This includes the Bayley Scale of Infant and Toddler Development – 3rd Edition despite the age
limit of 42 months.
Future research to explore therapeutic benefits of minocycline in AS should involve studies
with a placebo-controlled crossover design to better control for practice and temporal effects. The
study design also did not allow for evaluation of practice effects particularly from T1 to T2.
Previous research is replete with data indicating practice effects are present in neuropsychological
assessments and are often most pronounced between first and second testing periods and decrease
from second to third testing periods. It is important to point out that there are no published results
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studying practice effect in children with Angelman syndrome. Moreover, the calculated η2, the
results reported here show the associated improvement in neuropsychological measures reflected
an actual treatment effect not attributable to practice or error.
Conclusion
The data reported here show the administration of minocycline to children with Angelman
syndrome is safe and well tolerated. Moreover, we show minocycline improved the adaptive
behavior of these children suggesting this drug may be an effective treatment of this disorder. It is
important to determine the optimal treatment dosage as well as the effects of long-term use in this
patient population. Therefore, future controlled studies are recommended before minocycline is
used generally as a treatment for Angelman syndrome.
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CHAPTER 4

NEUROPSYCHOLOGICAL TESTING REVEALS THE NEED FOR A NOVEL
OUTCOME MEASURE IN THE ANGELMAN SYNDROME POPULATION
Background
Several genetic aberrations involving the UBE3A gene result in the expression of the AS
phenotype. In most tissues both the paternal and maternal alleles (chromosome 15q11.2) coding
for this protein are expressed equally (Jiang, Lev-Lehman et al. 1999). In contrast, neurons only
express the maternal allele; therefore, any mutation or deletion results in a non-functional gene
product (Albrecht, Sutcliffe et al. 1997). Normal expression of UBE3A results in the production of
ubiquitin protein ligase E3 (Ube3A), an enzyme that localizes to pre-synaptic and post-synaptic
compartments of neurons and is required for normal synaptic function (Gustin, Bichell et al. 2010).
Thus, there is an ongoing initiative by our lab and others to develop or identify a therapeutic with
the potential to restore synaptic function, which, in turn, may ameliorate the motor and cognitive
deficiencies experienced by individuals with AS. One major challenge in assessing the symptoms
in any single individual with AS is the wide etiologic variation and wide-ranging severity of known
symptoms.
There is an urgent need to identify outcome measures that are adequately sensitive,
specific, reliable and valid to demonstrate treatment benefit for pharmacologic interventions or
behavioral trials developed for use in Angelman syndrome, particularly in children. Our
experience revealed the severe developmental delay, cognitive impairment and deficits in speech
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prevent the child with AS from performing on the current neuropsychological tests. The cognitive
and behavioral assessments most typically used is the Bayley Scales of Infant and Toddler
Development-3rd Ed. (BSID-III; Bayley, 2005) and/or Vineland Adaptive Behavior Scales-2nd Ed.
(VABS; Sparrow et al., 2005). Due to the behavioral characteristics of the syndrome, all children
with AS exhibit raw scores at the bottom of the testing scale. This results in a lack of variance
between children (a floor effect) in which no difference between individuals can be seen (Figure
4-1) and, in the case of experimental therapeutics, small changes will not be detected.

Expressive & Receptive Communication Scores
Participant

1
2
3
4
5
6

Bayley III- ECC
Raw
15
12
12
7
18
17

Standard
1
1
1
1
2
1

Bayley III - RCC
Raw
13
15
15
9
30
15

Standard
2
3
3
1
7
3

Figure 4-1. Current Standardized Measures are Insensitive to the Cognitive and
Behavioral Abilities of Children with Angelman Syndrome.
A) Participant raw and scaled scores in the expressive (ECC) (16.2±2.9 & 3.2±1.0) and
receptive (RCC) (13.5±1.6 & 1.2±0.2) communication domains of the Bayley Scales of Infant
and Toddler Development. B) Participant raw and scaled scores in the expressive (40.7±4.8 &
1±0) and receptive (32.7±4.7 & 4.8±2.1) communication domains of the Vineland Adaptive
Behavior Scales.
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Our research has revealed the quantification of behavioral characteristics of Angelman
syndrome from recorded observations is possible and is reliable between raters. Moreover, we
show that children with AS use more primitive forms of communication which is likely related to
a childhood apraxia of speech compounded by deficits in receptive and expressive language.
Finally, children with Angelman syndrome exhibit not only a wide based gait, but other abnormal
parameters of gait that can be combined into an index and used as a potential biomarker when
therapeutics are applied. This research identifies, for the first time, a measure that quantifies an
individual’s overall level of severity of Angelman syndrome within the population and would in
turn facilitate assessment of natural development, behavioral modification, and therapeutic
intervention.
Methods
To date only 4 clinical research studies have been attempted in the Angelman syndrome
patient population. First, recruitment is still underway for an observational, longitudinal study
named the Natural History Study aimed a better understanding the natural progression of the
patient with AS throughout the lifespan. The second is a completed study in which folic acid
supplementation would increase expression of the paternal UBE3A allele by altering DNA
methylation (Peters, Bird et al. 2010). The researcher hypothesized the effect of folic acid
supplementation would be enhanced by the addition of betaine (Dan, Servais et al. 2004).The third,
is the ongoing clinical trial using levodopa which aims to increase fine motor ability by decreasing
the amount of tremor that is associated with the syndrome. Finally, our recently concluded clinical
trial using the antibiotic minocycline showed small but significant changes in communication and
self-care (Grieco, Ciarlone et al. 2014). In each of these four studies, outcome measures relied
upon neuropsychological tests including the Bayley Scales of Infant and Toddler Development
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(Bayley-III), Preschool Language Scale, 4th Edition (PLS-4), Aberrant Behavior Checklist (ABC)
and the Vineland Adaptive Behavior Scales (VABS) in order to make historical comparisons
between the results, and due to the lack of available alternatives.
Study Design
Currently, the clinical features of AS included in chapter 1 (Table 1-1) are used to diagnose
the disorder, which is then confirmed by a cytogenetic workup (Buntinx, Hennekam et al. 1995,
Williams, Beaudet et al. 2006). We are limited by an absence of a documented global scale for
these features in Angelman syndrome or even specific scales of dynamic range for each individual
feature. We identified several behavioral domains; communication, attention, maladaptive
behaviors, and hyper-excitability that are most disturbed in patients with Angelman syndrome.
Participants
Participants with Angelman syndrome were recruited through an Angelman syndrome
support group. A convenience sample of typically developing children were recruited from siblings
of the participants with AS and from the community. This study was reviewed and approved by
the University of South Florida’s, Human Research Protection Program’s Institutional Review
Board (Protocol Number Pro00004716). Signed informed consent was obtained by at least one
legally authorized representative prior to participation in this study. Moreover, assent was obtained
from each unaffected child 7 years of age or older. Inclusion and exclusion criteria required that
participants with AS have a molecular confirmation of their diagnosis and that they have not
received any therapeutic to treat the symptoms of AS within the preceding 12 months.
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Communication
To quantify the communication behavior, participants were placed in a room with a
licensed speech and language pathologist and engaged in an unstructured play session to elicit
speech and non-verbal communication attempts. Four cameras mounted in various positions
captured video recordings with audio. In addition, audio was recorded and analyzed using the
LENA Pro™ analysis system which segmented the audio recordings into vocalizations surrounded
by 300ms of silence. Speech attempts by the child were transcribed phonetically and categorized
into five different types of vocalizations using the Stark Assessment of Early Vocal DevelopmentRevised (SAEVD-R) (Nathani, Ertmer et al. 2006) which categorizes non-speech and pre-speech
sounds (protophones), as well as vowels, consonants and syllables. This 5 point scale differentiates
segments based on resonance, duration and speed of transition between sounds. Consonant-vowel
(CV) utterances were analyzed further into frequently occurring (labial/central, coronal/front,
velar/back) and less frequently occurring CV combinations (Giulivi, Whalen et al. 2011) and a
phonetic inventory was developed.
Video recordings of the session were analyzed for gesture use using Noldus Observer®
software. Gestures were classified (Table 4-1) as deictic (which establish reference by calling
attention to or indicating an object) or representational (which establish reference and indicate
specific semantic content) and the function of the gesture was established as: 1) Behavior
regulation -- requesting objects, protesting; 2) Social interaction -- including greetings, joint
attention (showing, commenting) and shared engagement (Crais, Watson et al. 2009). Children
who utilize more representational gestures and engage in more joint attention are more likely to
communicate verbally or use an augmentative communication device.
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Table 4-1. Gesture Function Subtypes
Gesture Function
Subtype
Deictic
Behavioral Regulation
Representational
Joint Attention
Social Interaction
Shared Engagement

Descriptive Example
Child reached for an object
Child pretended to drink from a cup when
holding an empty cup
Child focused on the same object as the
clinician
Child engaged in activity with the
clinician

Adaptive Behaviors
Adaptive behaviors of children with Angelman syndrome and healthy control children
were coded using the Noldus Observer® XT software as described in the communication section
above. Patients with AS have been described as hyper-active, that is, they spend little time in a
stationary position. As such, they tend not to focus on one particular task for any appreciable length
of time. While not an indication of their emotional state, persons with AS also exhibit a persistent
happy demeanor and show hyper-excitability by way of hand flapping and laughter, often at
inappropriate times. As with the assessment of communication, 3 independent reviewers,
quantified the frequency and duration of the behaviors; attention span, laughter and mobility from
video recordings. Later, these data were analyzed using descriptive statistical methods and Intrarater and Inter-rater reliability for each behavior was calculated.
Statistical Analysis
An omnibus analysis of the measurements collected using the Angelman syndrome
assessment instrument was analyzed by multivariate analysis of variance (MANOVA) to
determine the degree of association between each component of the scale and whether each
component of the measurement scale can effectively differentiate symptom severity among healthy
control and children with Angelman syndrome. Following omnibus analysis, Bonferroni planned
comparisons was utilized to isolate effects duration of non-specific noises, attention span,
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ambulation and laughter. The intra-class correlation (ICC) is a commonly used statistic to describe
the magnitude of disagreement between two or more raters (inter-rater reliability) or between a
single rater at two or more different time points (intra-rater reliability). To determine intra and
inter-rater reliability, results from 3 randomly selected participants, were coded by 4 independent
raters and recoded by the original rater. Absolute agreement was determined by calculating an ICC
coefficient using a two-way random model utilizing SPSS (IBM Corp. Released 2013. IBM SPSS
Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp). A coefficient value of ≥0.7 was
considered an acceptable level of reliability with value of ≥0.8 representing an ideal amount of
reliability (Hallgren 2012).
Gait Assessment
Gait abnormalities occur in every known case of AS. While some patients with AS may
not walk at all, neurologic examination reveals an unsteady, wide based gait (Figure 4-2), in

A

B
28

Angelman
Typical

Centimeters

24

LT Stride Length

3

20

1

16
12
8

LT Stride Width

4

LT Step Length

RT Stride Width

0

LT

RT

LT

2

RT

4
RT Step Length

Figure 4-2. Children with Angelman Syndrome Exhibit Gait Anomalies Including Such as
Wide Based Gait.
A) Stride width measurements of 6 children with Angelman Syndrome age 4 to 11, 𝑥 = 15.1
(left) and 𝑥 = 15.0 (right) (n=6) compared to healthy control children, 𝑥 = 9.7 (left) and 𝑥 = 9.63
(right), of the same age (n=5) reveal participants with AS require a larger base of support during
walking. The dotted rectangle indicates the average range, 𝑥 = 8.5 to 13.7, for typically
developing children ages 4 to 11. B) Analysis software calculates the stride width by measuring
the distance between the heel strike of one foot and the heel strike of the contralateral foot as
shown in (B). This results in two measure of stride width, left and right.
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conjunction with rigid, ataxic movements of the legs. Previous research has shown patients with
ataxia present with a widened base, unsteadiness, and irregularity of steps with veering to one side.
Further, analysis of temporo-spatial gait parameters in patients with ataxia (without AS), reveal
lower cadence and step length while gait velocity, step width, stance phase and outward rotation
is increased when ataxic gait measures are compared to age matched norms (Oberg, Karsznia et
al. 1993, Dusing and Thorpe 2007, Fiorillo, Rinaldi et al. 2010). As with language development,
current tests evaluating development provide limited assessment of walking or any ambulatory
method. During our evaluation, children with AS walked down an instrumented walkway (Zeno
Walkway, ProtoKinetics, Havertown, PA; manufactured by Zenometrics, Peekskill, NY) at a selfselected pace for 4 to 6 trials and gait parameters were determined using ProtoKinetics Movement
Analysis Software (PKMAS; ProtoKinetics, Havertown, PA). Due to behaviors inherent to the
syndrome, such as attention span and the inability to follow directions, not all data collected could
be used. As such, a minimum of 8 footfalls (left and right pairs) were used in the analysis. Partially
captured footfalls and footfalls not video recorded were excluded from the analysis. Five primary
spatiotemporal parameters were analyzed: cadence, gait velocity, stride width, step length and
percent stance. For each parameter, group means were used to complete a principal component
analysis (PCA) and a gait index was created for the data. This was completed using the mean and
standard deviation calculations from the typically developing (control) participants and calculating
z-scores for all the data points. To generate the participant’s performance on each component, the
z-scores were multiplied by the associated loading values for that component and summed. The
results represent a particular participant’s deviation from prototypical performance for that
component. Finally, the absolute values of each component score are summed to yield the
participant’s gait index. This number represents the overall deviation from prototypical gait (the
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average gait of controls). Stated plainly, as the gait index score increases (moves away from 0),
the more deviant the gait of the AS participant is from the average gait of the typically developing
participants.
Results
Communication
Speech attempts by 9 children with AS were transcribed and categorized into five different
types of vocalizations using the Stark Assessment of Early Vocal Development-Revised. Results of
our study (Figure 4-3) showed none of the children with AS used advance forms of vocalizations
(Diphthongs, Jargon, or Complex syllables). However, the mean frequency of reflexive (cry &
discomfort, vegetative sounds) vocalization was observed 11.25 times, control of phonation (single
consonant or consonant-vowel, chuckle/laughter) 25.5 times and expansion (single vowels, vowel
glides, squeals, marginal babbling) 17.88 times. Few canonical syllables (single consonant-vowel,
syllable strings, whispered vocalizations, or disyllables) were observed in the participants with AS
(5.67 times). In contrast, a cognitively matched, typically developing participant (n=1) used more
advanced levels of vocalizations including expansion (8 times), canonical syllables (50 times) and
advanced forms of vocalization (3 times).
While most of the vocalizations we observed were either laughter or isolated vowels, three of the
children with AS produced consonant-vowel (CV) combinations. These limited productions were
characterized as either labial/central or velar/back CV combinations (Giulivi, Whalen et al. 2011).
The phonetic inventories of the entire group of children with AS was limited to the following
consonants: /,m,n,j,w,h,b,d,g,k/. All children with AS produced the /j,w,h/ and either /m/ or /n/.
Approximately one-half of the children produced the plosives /b,d/ and only one child produced
/k,g/. In terms of vowels, the children with AS tended to use central and low vowels and a few
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children produced high vowels. These consonant patterns taken together with a preference for
either front or back vowel usage suggests little tongue movement during speech production, which
may be related to the presence of childhood apraxia of speech. It was also noted that the children
with AS kept their tongue in a central position within their mouth the majority of the time.

Vocalizations Using the SAEVD-R
ADVANCED FORMS

0

CANONICAL SYLLABLES

5.67

EXPANSION

17.88

CONTROL OF PHONATION

25.5

REFLEXIVE

11.25
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Figure 4-3. Children with AS Use Less Developed Forms of Communication.
Using an observational method of testing, the frequency of vocalization for patients with
Angelman syndrome was measured. Vocalizations were then categorized using the Stark
Assessment of Early Vocal Development - Revised. Results revealed participants with AS most
commonly used single consonant, consonant-vowel or laughter forms of communication (control
of phonation) suggesting these children possess the vocal ability of a very young child (< 2 years
of age).
Considering the speech production findings mentioned above, we investigated the use of
gestures as a form of communication in this Angelman population. Using the Noldus Observer ®
XT software, gesture function (Table 4-2) was coded as behavioral regulation or social interaction
and further classified as deictic or representational (with in the behavioral regulation category) and
joint attention or shared engagement (with in the social interaction category).
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Table 4-2. Characterization of Gesture Use in Children with Angelman Syndrome
# of
Average
Mean Number of
participants
Percentage of
Gesture
Gestures Used
Subcategory
(AS) in which
Time Spent
Function
the behavior
TYPICAL
TYPICAL
AS
AS
N=1
N=1
was observed
No Gestures
Behavioral
Regulation

Social
Interactive

-

50.0%

29.43%

-

-

Deictic

9

16.55%

18.12%

28.92

18.12

Representational

1

0.27%

0%

3.87

0

Joint Attention

9

15.71%

37.05%

19.89

19.71

Shared Engagement

5

The short attention span of children with
AS made it difficult to discern between
joint attention and shared engagement.

These data show: 1) Children with AS used relatively equal amounts of the earlier
occurring gesture types (deictic gestures and joint attention). 2) Children with AS spent nearly
twice as much time not gesturing when compared to typically developing, younger children. 3)
Typically developing children spent more time in joint attention and used fewer deictic gestures
to communicate than the children with AS. 4) Representational gesture use was only observed in
1 child with AS. 5) Overall, the children with AS performed differently than the typically
developing children, emphasizing be havioral regulation more than social interaction in the
communicative attempts.
Adaptive Behavior:
Using the Noldus Observer® XT software, 30 minute video recordings (with audio) were coded
and behaviors characteristic to Angelman syndrome were quantified (Williams 2010). Results of
an Omnibus MANOVA test revealed a significant difference [F(5,10) = 19.602, p < 0.05] between
participants with AS (n=7) and the typically developing children (n=9) existed. As expected, we
observed large differences in the attention span (mean % of time = 5.0) and a significant difference
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[F(1,14) = 124.5, p < 0.05] in inappropriate laughter (mean % of time = 23.2) of participants with
AS when compared to typically developing children who showed an increase the length of
attention (mean % of time = 19.6) and a decrease in inappropriate laughing (mean % of time = 0.7)
respectively (Figure 4-4). Interestingly, children with AS spent a similar amount of time making
non-specific noises (sound emitted from the mouth but not vocalizations) compared to typically
developing children. However, when we coded non-specific noises in conjunction with intention
(attempts to respond or gain interaction with the examiner), results of children with AS (mean %
of time = 1.8) were twice that of the control group (mean % of time = 0.9).

Attention Span

Laughter
40.0

40.0

Mean % Time

Mean % Time

50.0

30.0
20.0
19.6

10.0
0.0

5.0

AS

TYP

30.0
20.0

23.2

10.0
0.7

0.0

AS

TYP

Figure 4-4. Analysis of Behavioral Coding Reveals Stark Differences Between Individuals
with AS and Typically Developing Participants.
These results coincide with the previously reported characteristic behaviors of Angelman
syndrome. More variation exists between children with AS than the control group suggesting a
large sample size is required in order to develop a scale for standardized comparisons.

Gait Assessment
Measure of spatiotemporal gait parameters (Table 4-3) revealed children with Angelman
syndrome exhibit decreased cadence and step length but an increase in stride width, % stance, gait
velocity and Base width which has recapitulated the results of Fiorillo et al. in patients with ataxia
without cognitive impairment (Fiorillo, Rinaldi et al. 2010, Prosser, Lauer et al. 2010). In contrast,
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these results reveal a stark contrast between children with AS and typically developing children as
well those with cerebral palsy and other mental disorders (Wondra, Pitetti et al. 2007, Prosser,
Lauer et al. 2010).
Table 4-3. Spatiotemporal Parameters of Gait for Children with Angelman Syndrome
Compared to Previously Reported Models of Ataxia and Norms from
Typically Developing Children
Norms
(3 to 9
yrs)

Fiorillo et
al. (2010)
ATX

n = 10
Prosser et
al. (2010)
CP

n = 10
Prosser et
al. (2010)
TD

n = 19
Wondra et
al. (2010)
MD

Cadence
(steps/min)

138.14 120.23

116

103.3

155.2

107.6

110.5

Step Length (m)

0.5

0.45

0.55

0.76

0.75

0.44

Stride Width (m)

0.05

0.1

-

-

-

0.15

% Stance Phase

40

59.3

77.5

84.8

80

60.1

Gait Velocity
(m/s)

0.89 - 1.10

0.87

0.22

-

0.64

0.81

Base Width (cm)

8.5 – 13.7

-

-

-

13.4

15.6

n = 13
GASA

ATX: Ataxia Only CP: Cerebral Palsy TD: Typically Developing MD: Various Mental
Disabilities GASA: Global Angelman Syndrome Assessment

A principal component analysis revealed 2 components of gait: 1) The gait velocity is
determined by the step length and that these two factors are inversely related to stride width. In
other words, as the stride width increases, as in the case of AS (ataxia), gait velocity decreases. 2)
An inverse relationship exists between cadence and percent stance. Specifically, as the percent of
time in contact with the ground increases the cadence decreases. This is intuitive since the cadence
equals the number of steps per time (min). Subsequent calculation of index scores revealed a mean
Gait Index of 3.16 ± 0.48 for typically developing participants and a Gait index of 4.94 ± 0.65 for
participants with AS. An independent t- test with Welch’s correction for unequal group variances
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indicated a significant difference between the two groups, t(22) = 2.201, p < 0.05, with Angelman
patients exhibiting impaired gait relative to controls.
Reliability Testing
Communication
Two speech samples (18%) were randomly selected and re-transcribed by the original transcriber.
Intra-rater agreement was 99%. The agreement of gesture coding was accomplished by recoding
20% of sessions. The original rater recoded 20 minute sections (minutes 5-25) from three randomly
selected participants for intra-rater agreement. Intra-rater agreement was 97%. One of the original
speech-language pathologists recoded three different, randomly selected participants for inter-rater
agreement. Inter-rater agreement was 78%. This value was deemed adequate since children with
AS do not use social communication in the same way as typical developing children. At times, it
was difficult to determine the child's intent. For instance, it was difficult to determine if play
stopped because the child lost interest or if they were indicating that they no longer wanted to play.
Miles and Huberman report an average agreement percentage of approximately 70% is adequate
for the preliminary use of a qualitative approach in a novel way (Miles and Huberman 1994).
Adaptive Behavior
Poor ICC coefficients (ICC < 0.7) were revealed when coding results from each of the 4
raters for 3 randomly selected participants were compared suggesting a larger than desired
variability between raters (Table 4-4). For instance, ICC coefficients were lower when multiple
raters coded more subjective behaviors such as noises with intention, inappropriate laughter and
attention span. However, for behaviors that are more easily defined, such as ambulation (any form
including but not limited to: walking, crawling or scooting), coding between raters was shown to
be reliable (ICC = 0.716). In contrast, an ICC greater than 0.8 was observed for each of the rated
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behaviors when coding results from the same rater at two different time points was compared,
which is evidence for the repeatability of these measurements utilizing the same rater.
Table 4-4. Statistical Analysis of Reliability Using the Intra-class Correlation
Coefficient
Inter-rater Reliability
Intra-rater Reliability
ICC
95% CI
ICC
95% CI
0.554
-0.495
0.987
0.831
-0.34 10.995
Noises w/ intent
0.448
-3.733
0.987
Inappropriate Laughter
Attention Span

0.427

-1.293

0.896

0.836

0.089

0.976

Ambulation

0.716

-6.717

1.000

0.837

-13.2

0.996

Two-way random effect model where both rater and measure effects are random. Calculations
of ICC are using an absolute agreement definition. For inter and intra-rater reliability, an
instrument should be considered reliable when the intra-lass correlation coefficient ≥0.7,
however, ≥0.8 is ideal. No laughter was observed in the randomly selected participants,
therefore ICC for inappropriate laughter could not be calculated.

Discussion
Previous clinical research has shown the development of a novel outcome measure for
patients with Angelman syndrome is a necessity (Grieco, Ciarlone et al. 2014) to detect change
when a therapeutic is administered. The behavioral traits inherent to the syndrome, coupled with
severe cognitive impairment, interfere with the child’s ability to perform the tasks required to score
above the floor of the instrument. This is not to say they cannot complete the tasks, rather, most
children with AS are capable of performing the more complex tasks of the Bayley Scales of Infant
and Toddler Development, but will not complete the task as commanded or in the allotted time.
As the pipeline for potential therapeutics to treat AS is developed, a measure that can detect a
change in behavior and ability in this complex population will be required.
Of the control group, only two participants were younger than the participants with AS.
However, they demonstrated more advanced communication skills than the children with AS.
Analysis of the results suggests they desired the socialization aspect of communication more than
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those with AS, who used primitive communication types to meet their needs. For instance, some
of the children with AS would touch, hit or attempt to bite the clinician, showing a desire to interact
and their lack of understanding of how to communicate appropriately.
As expected, the typically developing children seemed to prefer to use words more than
gestures to communicate while very few verbalizations, other than laughter, were elicited from the
children with AS. The participants with AS demonstrated a higher level of receptive language skill
than evidenced in their expression. For instance, they occasionally responded to clinician requests
and they would stop an inappropriate behavior when asked. Few consonant and vowel patterns
were observed, suggest the presence of childhood apraxia of speech. We also noted that the tongue
of the participants with AS moves very little during speech production, remaining in a central
position within the mouth.
Using behavioral coding software, we were able to capture and quantify the behavioral
characteristics of a child with Angelman syndrome. Moreover, when a specific behavioral domain,
such as communication, was compared amongst new and existing instruments, it was clear the use
of an observational method gives rise to more sensitive results demarcating a wide variation in
ability among children with Angelman syndrome. This increase in measureable variation between
individuals allows us to use parametric analysis for determining an individual’s disorder severity
compared to other children with Angelman syndrome as well as highlight particularly small
changes in behaviors, either regression or improvement, when therapeutics are applied. While
intra-rater reliability was shown to be ideal, the low ICC values for inter-rater reliability indicate
large differences in the coding of each rater. These results suggest: 1) Clear definitions of each
category of behavior and any sub category are needed prior to experimentation. 2) A considerable
amount of training should be received and an ICC calculated for a particular rater prior to coding
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behavior during an ongoing study. This training should include several mock coding sessions in
order for the rater to become familiar with behavioral definitions and software functions. This is
not uncommon as several standardized exams require certification of the examiner. 3) Whenever
possible, the same rater should code both baseline and any post treatment recordings. 4) A standard
set of interactions with the participant during behavioral observation may be necessary in order to
elicit similar responses between participants.
While the assessment of behavior and communication is important, quality of ambulation
is paramount to the quality of life for patients with Angelman syndrome. Until recently, gait
analysis was a tedious task involving the mapping of a patient’s steps and subsequent calculation
of numerous gait parameters. Here, using an electronic walkway and PKMAS analysis software,
we have shown mean gait measurements for 5 parameters of gait said to have the most contribution
to an ataxic gait. Consistent with the results of Fiorillo et al., results from participants with AS
were most closely related to patients with ataxia but without cognitive impairment. Similar to an
apraxia of speech, these results suggest the disability observed in the AS patient population may
be due to an inability of the brain to communicate properly with the extremities. Further, our ability
to capture and quantify these spatiotemporal parameters of gait suggests these measures could be
used as a biomarker when an applied therapeutic is suspected to alter gait.
Conclusion
Angelman syndrome researchers agree, the neuropsychological outcome measures that
exist currently do not accurately measure the cognition, communication, or motor ability of a child
with Angelman syndrome. Due to the instrument’s inability to capture changes when a therapeutic
is applied, researchers risk reporting false negative results even if a positive effect exists. The
results of this study show that not only can we capture, quantify and analyze the adaptive behavior
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and motor ability of patients with Angelman syndrome; we can do it with specificity. This means
the Global Angelman Syndrome Assessment will detect even the smallest amount of change during
clinical studies of new therapeutics for this devastating disorder.
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CHAPTER 5

DISCUSSION
Summary
Angelman syndrome (AS) is a congenital disorder caused by an aberration of the maternal
15q11-13 locus of chromosome 15. These include: deletion (65% of cases), mutation (10%),
paternal uniparental disomy (5%), and defect of the imprinting center (5%). Still, another 15% of
patients present with the clinical features of AS, but no molecular abnormality can be detected.
Therefore, diagnosis of AS is dependent on the presence of certain characteristic features of the
syndrome including: difficulty feeding as neonates and infants, truncal hypotonacity (6-12 months)
with rigid, jerky movement of the extremities. Disorders in balance and movement continue
throughout the patients lifespan and result in characteristic “marionette style” gait. Approximately
80% of children with AS also suffer from seizures and display a characteristic
electroencephalogram pattern which is useful in the diagnosis of the syndrome especially when
molecular testing results are negative.
Abnormalities in the density and morphology dendritic spines have been shown in the AS
mouse as well as 1 human female with AS. Moreover, AS mice exhibit severe LTP deficits and
impaired associative learning. However, studies by our lab, and others, show recovery of the major
AS phenotypes is possible in the adult AS mouse. These results indicate AS arises from
biochemical alterations rather that developmental abnormalities. Furthermore, the severity of the
AS phenotype is likely due to a disorder in global synaptic function.
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The mechanism by which the lack of one particular protein, UBE3A, can result in such
severe global dysfunction is still unknown. To date UBE3A has not been shown to be associated
with any memory associated protein target. However, the lack or mutation of UBE3A leads to
alterations in the amount and/or activity of proteins known to play a role in learning and memory
(i.e. CaMKII, Erk and potassium ATPase) in the AS mouse. For example, when an additional
mutation in the inhibitory phosphorylation site of CaMKII was introduced in the AS mouse, a
recovery of the behavioral deficits normally associated with these mice was observed.
The aforementioned results suggest a reduction in global synaptic function underlies the
learning and memory phenotype of AS. A therapeutic with the potential to normalize the aberrant
synaptic function may result in a recovery of these defects. We show AS mice treated with both
high and low dosages of minocycline exhibited an increase in dendritic spine density and LTP
when compared to saline treated AS control mice. Moreover, density of spines was increased to
the level of wild type animals. AS animals receiving the lower dosage also showed an increase in
associative learning behavior. This suggests that while minocycline alters the structure of dendritic
spines and the function of synapses, higher dosages can have a detrimental effect on behaviors
such as learning and memory. It is important to point out, that while we are measuring changes
using the hippocampus as a model, the effects minocycline has on structure and function of spines
and synapses are global and not limited to any one brain region and that this global effect is needed
in order to achieve changes in behavioral output.
Conclusion
The field of AS research has rapidly expanded, especially over the last few years, with the
identification of several potential therapeutics. Differing strategies have focused on replacing the
missing protein (through the insertion of a viral vector) or increasing paternal expression by
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“unlocking” the paternal gene (i.e. topoisomerase inhibitors and antisense oligonucleotides).
While conceptually these therapies possess the potential to increase UBE3A protein in the AS
brain, the side effects, potential toxicity, invasiveness of the administration and the unclear
mechanism of the imprinting is likely to significantly increase the time to translation for AS
patients.
The main focus of my work is to quickly translate potential therapeutics from the laboratory
to the human by investigating small molecule compounds, approved by the FDA for use in humans,
that possess the potential to improve learning and memory in the AS mouse model.
I have shown one such compound, minocycline, has the ability to normalize dendritic spine
density, increase LTP and improve hippocampal-dependent memory and in the AS mouse. In a
human study, I have shown short-term (8 week) use of minocycline is safe and well tolerated in
children with Angelman syndrome. While we did not observe changes in EEG recordings,
significant improvement in the clinical global impressions severity scores suggest an improvement
in symptoms was observed by a child neurologist. Small but significant improvement in the
adaptive behaviors, communication and self-care were also observed.
Unfortunately, the available neuropsychological measures were not designed for a patient
population with severe disabilities. The lack of performance ability resulted in an inability to
accurately portray the ability of these patients with AS. For this reason, I began to develop a novel
outcome measure that relies on the behavioral observation rather than the verbal ability of children
with AS. Using behavior coding software, I find that specific behaviors of these patients can be
quantified with a high level of intra-rater reliability. Analysis of communication behavior shows
the presence a childhood apraxia rather than an inability to learn or understand. Moreover the
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analysis of gait parameters revealed similar results to patients with ataxia without cognitive
impairment.
The culmination of my work has provided evidence that a treatment for Angelman
syndrome is probable. I have shown minocycline has potential to improve synaptic function and
learning and memory in AS mice and alter certain behaviors in humans. Elucidation by which
minocycline can recover cognitive impairment in the AS mouse model may shed light on novel
therapeutic targets for future AS research. Finally, the development of a novel outcome measure,
specific to Angelman syndrome will provide an accurate assessment of changes in behavior when
a therapeutic is applied.
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